0000744825 AMERICAN SHARED HOSPITAL SERVICES false --12-31 Q3 2024 100,000 100,000 156,000 250,000 0 0 10,000,000 10,000,000 6,390,000 6,390,000 6,300,000 6,300,000 88,000 1,314,000 10 2 11 2 1 3 3 10 3 5 123,000 123,000 3 1 3 false false false false 0000744825 2024-01-01 2024-09-30 xbrli:shares 0000744825 2024-11-08 iso4217:USD 0000744825 2024-09-30 0000744825 2023-12-31 0000744825 us-gaap:RelatedPartyMember 2024-09-30 0000744825 us-gaap:RelatedPartyMember 2023-12-31 iso4217:USD xbrli:shares 0000744825 ams:RentalIncomeFromMedicalServicesMember 2024-07-01 2024-09-30 0000744825 ams:RentalIncomeFromMedicalServicesMember 2023-07-01 2023-09-30 0000744825 ams:RentalIncomeFromMedicalServicesMember 2024-01-01 2024-09-30 0000744825 ams:RentalIncomeFromMedicalServicesMember 2023-01-01 2023-09-30 0000744825 ams:PatientIncomeMember 2024-07-01 2024-09-30 0000744825 ams:PatientIncomeMember 2023-07-01 2023-09-30 0000744825 ams:PatientIncomeMember 2024-01-01 2024-09-30 0000744825 ams:PatientIncomeMember 2023-01-01 2023-09-30 0000744825 ams:EquipmentSalesMember 2024-07-01 2024-09-30 0000744825 ams:EquipmentSalesMember 2023-07-01 2023-09-30 0000744825 ams:EquipmentSalesMember 2024-01-01 2024-09-30 0000744825 ams:EquipmentSalesMember 2023-01-01 2023-09-30 0000744825 2024-07-01 2024-09-30 0000744825 2023-07-01 2023-09-30 0000744825 2023-01-01 2023-09-30 0000744825 us-gaap:CommonStockMember 2022-12-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000744825 us-gaap:RetainedEarningsMember 2022-12-31 0000744825 us-gaap:ParentMember 2022-12-31 0000744825 us-gaap:NoncontrollingInterestMember 2022-12-31 0000744825 2022-12-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000744825 us-gaap:ParentMember 2023-01-01 2023-03-31 0000744825 2023-01-01 2023-03-31 0000744825 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000744825 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000744825 us-gaap:CommonStockMember 2023-03-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000744825 us-gaap:RetainedEarningsMember 2023-03-31 0000744825 us-gaap:ParentMember 2023-03-31 0000744825 us-gaap:NoncontrollingInterestMember 2023-03-31 0000744825 2023-03-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000744825 us-gaap:ParentMember 2023-04-01 2023-06-30 0000744825 2023-04-01 2023-06-30 0000744825 us-gaap:RestrictedStockMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000744825 us-gaap:RestrictedStockMember 2023-04-01 2023-06-30 0000744825 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000744825 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000744825 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0000744825 us-gaap:CommonStockMember 2023-06-30 0000744825 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000744825 us-gaap:RetainedEarningsMember 2023-06-30 0000744825 us-gaap:ParentMember 2023-06-30 0000744825 us-gaap:NoncontrollingInterestMember 2023-06-30 0000744825 2023-06-30 0000744825 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000744825 us-gaap:ParentMember 2023-07-01 2023-09-30 0000744825 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000744825 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000744825 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0000744825 us-gaap:CommonStockMember 2023-09-30 0000744825 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000744825 us-gaap:RetainedEarningsMember 2023-09-30 0000744825 us-gaap:ParentMember 2023-09-30 0000744825 us-gaap:NoncontrollingInterestMember 2023-09-30 0000744825 2023-09-30 0000744825 us-gaap:CommonStockMember 2023-12-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000744825 us-gaap:RetainedEarningsMember 2023-12-31 0000744825 us-gaap:ParentMember 2023-12-31 0000744825 us-gaap:NoncontrollingInterestMember 2023-12-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000744825 us-gaap:ParentMember 2024-01-01 2024-03-31 0000744825 2024-01-01 2024-03-31 0000744825 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000744825 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000744825 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000744825 us-gaap:CommonStockMember 2024-03-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000744825 us-gaap:RetainedEarningsMember 2024-03-31 0000744825 us-gaap:ParentMember 2024-03-31 0000744825 us-gaap:NoncontrollingInterestMember 2024-03-31 0000744825 2024-03-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000744825 us-gaap:ParentMember 2024-04-01 2024-06-30 0000744825 2024-04-01 2024-06-30 0000744825 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000744825 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000744825 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0000744825 us-gaap:CommonStockMember 2024-06-30 0000744825 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000744825 us-gaap:RetainedEarningsMember 2024-06-30 0000744825 us-gaap:ParentMember 2024-06-30 0000744825 us-gaap:NoncontrollingInterestMember 2024-06-30 0000744825 2024-06-30 0000744825 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000744825 us-gaap:ParentMember 2024-07-01 2024-09-30 0000744825 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000744825 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000744825 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0000744825 us-gaap:CommonStockMember 2024-09-30 0000744825 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000744825 us-gaap:RetainedEarningsMember 2024-09-30 0000744825 us-gaap:ParentMember 2024-09-30 0000744825 us-gaap:NoncontrollingInterestMember 2024-09-30 xbrli:pure 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2023-11-10 2023-11-10 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2023-11-10 0000744825 ams:NewcoGuadalajaraMember 2024-06-28 0000744825 ams:HsjMember ams:NewcoGuadalajaraMember 2024-06-28 0000744825 ams:NewcoMember 2022-04-27 0000744825 ams:GuadalupeMember ams:NewcoMember 2022-04-27 0000744825 ams:OR21LLCMember 2024-09-30 0000744825 ams:ArchitecturalDesignCompanyMember ams:OR21LLCMember 2024-09-30 0000744825 ams:PbrtServicesMember 2024-07-01 2024-09-30 0000744825 ams:PbrtServicesMember 2024-01-01 2024-09-30 0000744825 ams:PbrtServicesMember 2023-07-01 2023-09-30 0000744825 ams:PbrtServicesMember 2023-01-01 2023-09-30 0000744825 country:MX 2024-09-30 0000744825 ams:RiCompaniesMember 2024-05-07 utr:D 0000744825 ams:RiCompaniesMember srt:MinimumMember 2024-05-07 0000744825 ams:RiCompaniesMember srt:MaximumMember 2024-05-07 0000744825 ams:GKCEMember 2024-09-30 0000744825 ams:GKCEMember 2024-01-01 0000744825 ams:GKCEMember 2023-09-30 0000744825 ams:GKCEMember 2023-01-01 0000744825 ams:GKCEMember 2024-07-01 2024-09-30 0000744825 ams:GKCEMember 2024-01-01 2024-09-30 0000744825 ams:GKCEMember 2023-07-01 2023-09-30 0000744825 ams:GKCEMember 2023-01-01 2023-09-30 0000744825 ams:GammaKnifeAndPBRTEquipmentMember 2024-09-30 0000744825 ams:LimaPeruAndGuayaquilEcuadorMember 2024-09-30 0000744825 ams:SingleunitRadiationTherapyFacilitiesMember 2024-05-07 0000744825 ams:MedicalEquipmentLeasingMember 2024-07-01 2024-09-30 0000744825 ams:MedicalEquipmentLeasingMember 2023-07-01 2023-09-30 0000744825 ams:MedicalEquipmentLeasingMember 2024-01-01 2024-09-30 0000744825 ams:MedicalEquipmentLeasingMember 2023-01-01 2023-09-30 0000744825 ams:DirectPatientServicesMember 2024-07-01 2024-09-30 0000744825 ams:DirectPatientServicesMember 2023-07-01 2023-09-30 0000744825 ams:DirectPatientServicesMember 2024-01-01 2024-09-30 0000744825 ams:DirectPatientServicesMember 2023-01-01 2023-09-30 utr:Y 0000744825 ams:MedicalAndOfficeEquipmentMember srt:MinimumMember 2024-09-30 0000744825 ams:MedicalAndOfficeEquipmentMember srt:MaximumMember 2024-09-30 0000744825 ams:PBRTEquipmentMember 2024-09-30 0000744825 ams:MedicalEquipmentAndFacilitiesMember 2024-09-30 0000744825 ams:MedicalEquipmentAndFacilitiesMember 2023-12-31 0000744825 us-gaap:OfficeEquipmentMember 2024-09-30 0000744825 us-gaap:OfficeEquipmentMember 2023-12-31 0000744825 us-gaap:ConstructionInProgressMember 2024-09-30 0000744825 us-gaap:ConstructionInProgressMember 2023-12-31 0000744825 us-gaap:NonUsMember 2024-09-30 0000744825 us-gaap:NonUsMember 2023-12-31 0000744825 ams:TheCreditAgreementMember ams:FifthThirdBankNAMember 2021-04-09 0000744825 ams:TheCreditAgreementFirstLoanAndSecondLoanFacilityMember ams:FifthThirdBankNAMember 2021-04-09 0000744825 ams:TheCreditAgreementSecondLoanFacilityMember ams:FifthThirdBankNAMember 2021-04-09 0000744825 us-gaap:RevolvingCreditFacilityMember ams:TheCreditAgreementThirdLoanFacilityMember ams:FifthThirdBankNAMember 2021-04-09 0000744825 us-gaap:RevolvingCreditFacilityMember ams:TheCreditAgreementThirdLoanFacilityMember ams:FifthThirdBankNAMember 2024-09-30 0000744825 us-gaap:RevolvingCreditFacilityMember ams:TheCreditAgreementThirdLoanFacilityMember ams:FifthThirdBankNAMember 2021-04-09 2021-04-09 0000744825 us-gaap:RevolvingCreditFacilityMember ams:TheCreditAgreementThirdLoanFacilityMember ams:FifthThirdBankNAMember ams:LondonInterbankOfferedRateMember 2021-04-09 2021-04-09 0000744825 ams:TheCreditAgreement2024SupplementalTermLoanMember ams:FifthThirdBankNAMember 2024-01-25 0000744825 ams:TheCreditAgreement2024SupplementalTermLoanMember ams:FifthThirdBankNAMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-25 2024-01-25 0000744825 ams:TheCreditAgreementFirstLoanAndSecondLoanFacilityMember ams:FifthThirdBankNAMember 2024-09-30 0000744825 ams:TheCreditAgreementFirstLoanAndSecondLoanFacilityMember ams:FifthThirdBankNAMember 2023-12-31 0000744825 ams:TheCreditAgreement2024SupplementalTermLoanMember ams:FifthThirdBankNAMember 2024-09-30 0000744825 ams:TheCreditAgreementMember ams:FifthThirdBankNAMember 2021-04-09 2021-04-09 0000744825 ams:DfcLoanTrancheOneMember 2024-09-30 0000744825 ams:DfcLoanTrancheTwoMember 2024-03-31 0000744825 ams:DfcLoanMember 2024-09-30 0000744825 ams:DfcLoanMember 2023-12-31 utr:sqft 0000744825 ams:SubleaseOfficeInSanFranciscoCaliforniaMember 2021-11-03 0000744825 ams:SubleaseOfficeInSanFranciscoCaliforniaMember 2021-11-03 2021-11-03 0000744825 ams:LeaseAgreementForNewCorporateOfficeMember 2021-11-03 0000744825 ams:LeaseAgreementForNewCorporateOfficeMember 2021-11-03 2021-11-03 0000744825 ams:WoonsocketOperatingLeaseMember 2024-05-07 0000744825 us-gaap:RelatedPartyMember 2024-07-01 2024-09-30 0000744825 us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000744825 ams:WoonsocketOperatingLeaseMember us-gaap:RelatedPartyMember 2024-09-30 0000744825 srt:MinimumMember 2024-09-30 0000744825 srt:MaximumMember 2024-09-30 0000744825 stpr:RI 2024-09-30 0000744825 us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0000744825 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0000744825 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0000744825 us-gaap:RestrictedStockMember 2024-07-01 2024-09-30 0000744825 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000744825 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0000744825 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000744825 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0000744825 us-gaap:RestrictedStockMember 2023-07-01 2023-09-30 0000744825 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0000744825 ams:IncentiveCompensationPlanMember 2021-06-30 0000744825 ams:IncentiveCompensationPlanMember 2024-09-30 0000744825 2023-01-01 2023-12-31 0000744825 srt:MinimumMember 2024-01-01 2024-09-30 0000744825 2022-01-01 2022-12-31 0000744825 srt:MaximumMember 2024-01-01 2024-09-30 0000744825 ams:LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember 2024-01-01 2024-09-30 0000744825 ams:LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember 2024-09-30 0000744825 ams:MaintenanceAndSupportAgreementMevionServiceAgreementMember ams:MevionMedicalSystemsIncMember 2024-09-04 0000744825 ams:MaintenanceAndSupportAgreementMevionServiceAgreementMember ams:MevionMedicalSystemsIncMember 2022-09-04 2022-09-04 0000744825 srt:MinimumMember ams:LINACSystemMember 2024-01-01 2024-09-30 0000744825 ams:LINACSystemMember 2024-09-30 0000744825 ams:GKFSubsidiaryMember 2024-09-30 0000744825 ams:USSubsidiaryOfElektaMember 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember ams:GeDiscoveryRtCtSimulatorMember 2024-04-18 2024-04-18 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2024-07-01 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2024-05-07 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember us-gaap:ChangeDuringPeriodFairValueDisclosureMember 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember ams:MedicalEquipmentMember 2024-05-07 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember us-gaap:ChangeDuringPeriodFairValueDisclosureMember ams:MedicalEquipmentMember 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember ams:MedicalEquipmentMember 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember ams:MedicalFacilitiesMember 2024-05-07 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember us-gaap:ChangeDuringPeriodFairValueDisclosureMember ams:MedicalFacilitiesMember 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember ams:MedicalFacilitiesMember 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2024-05-07 2024-05-07 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember us-gaap:ChangeDuringPeriodFairValueDisclosureMember 2024-05-07 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2024-09-30 2024-09-30 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2024-01-01 2024-09-30 thunderdome:item

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024 or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________.

Commission file number 001-08789

American Shared Hospital Services

(Exact name of registrant as specified in its charter)

California | 94-2918118
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.)

601 Montgomery Street | Suite 1112 | San Francisco, | California | 94111-2619
(Address of principal executive offices) | (Zip code)

(415) 788-5300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
American Shared Hospital Services Common Stock, No Par Value | AMS | NYSEAMER

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐ | Accelerated Filer ☐ | Non-Accelerated Filer ☒ | Smaller reporting company ☒
Emerging Growth Company ☐ |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 8, 2024, there were outstanding 6,420,000 shares of the registrant’s common stock.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

AMERICAN SHARED HOSPITAL SERVICES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

ASSETS |  | September 30, 2024 |  |  | December 31, 2023 |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 13,827,000 |  |  | $ | 13,690,000 |
Restricted cash |  |  | 250,000 |  |  |  | 118,000 |
Accounts receivable, net of allowance for credit losses of $100,000 at September 30, 2024 and at December 31, 2023 |  |  | 8,635,000 |  |  |  | 4,343,000 |
Other receivables |  |  | 1,306,000 |  |  |  | 504,000 |
Prepaid maintenance |  |  | 945,000 |  |  |  | 1,275,000 |
Prepaid expenses and other current assets |  |  | 757,000 |  |  |  | 526,000 |
Total current assets |  |  | 25,720,000 |  |  |  | 20,456,000 |
Property and equipment, net |  |  | 34,807,000 |  |  |  | 25,844,000 |
Land |  |  | 19,000 |  |  |  | 19,000 |
Goodwill |  |  | 1,265,000 |  |  |  | 1,265,000 |
Intangible asset |  |  | 78,000 |  |  |  | 78,000 |
Right of use assets, net |  |  | 986,000 |  |  |  | 57,000 |
Other assets |  |  | 394,000 |  |  |  | 443,000 |
Total assets |  | $ | 63,269,000 |  |  | $ | 48,162,000 |
LIABILITIES AND SHAREHOLDERS' EQUITY |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,786,000 |  |  | $ | 315,000 |
Employee compensation and benefits |  |  | 1,223,000 |  |  |  | 757,000 |
Other accrued liabilities |  |  | 1,966,000 |  |  |  | 1,226,000 |
Related party liabilities |  |  | 3,544,000 |  |  |  | 1,961,000 |
Asset retirement obligations, related party (includes $156,000 and $250,000 non-related party at September 30, 2024 and December 31, 2023) |  |  | 750,000 |  |  |  | 650,000 |
Income taxes payable |  |  | - |  |  |  | 1,229,000 |
Current portion of lease liabilities |  |  | 235,000 |  |  |  | 57,000 |
Line of credit |  |  | 4,500,000 |  |  |  | 2,500,000 |
Current portion of long-term debt, net |  |  | 3,557,000 |  |  |  | 2,084,000 |
Total current liabilities |  |  | 17,561,000 |  |  |  | 10,779,000 |
Long-term lease liabilities, less current portion |  |  | 1,500,000 |  |  |  | - |
Long-term debt, net, less current portion |  |  | 10,818,000 |  |  |  | 11,041,000 |
Deferred income taxes |  |  | 1,560,000 |  |  |  | 63,000 |
Total liabilities |  |  | 31,439,000 |  |  |  | 21,883,000 |
Commitments (see Note 9) |  |  |  |  |  |  |  |
Shareholders' equity: |  |  |  |  |  |  |  |
Common stock, no par value (10,000,000 authorized shares; Issued and outstanding shares - 6,390,000 at September 30, 2024 and 6,300,000 at December 31, 2023) |  |  | 10,763,000 |  |  |  | 10,763,000 |
Additional paid-in capital |  |  | 8,517,000 |  |  |  | 8,232,000 |
Retained earnings |  |  | 7,143,000 |  |  |  | 3,629,000 |
Total equity-American Shared Hospital Services |  |  | 26,423,000 |  |  |  | 22,624,000 |
Non-controlling interests in subsidiaries |  |  | 5,407,000 |  |  |  | 3,655,000 |
Total shareholders' equity |  |  | 31,830,000 |  |  |  | 26,279,000 |
Total liabilities and shareholders' equity |  | $ | 63,269,000 |  |  | $ | 48,162,000 |

See accompanying notes

1

AMERICAN SHARED HOSPITAL SERVICES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rental revenue from medical equipment leasing |  | $ | 3,312,000 |  |  | $ | 3,946,000 |  |  | $ | 11,464,000 |  |  | $ | 12,987,000 |
Direct patient services revenue |  |  | 3,687,000 |  |  |  | 988,000 |  |  |  | 7,807,000 |  |  |  | 2,440,000 |
Equipment sales, net |  |  | - |  |  |  | 200,000 |  |  |  | - |  |  |  | 200,000 |
|  |  | 6,999,000 |  |  |  | 5,134,000 |  |  |  | 19,271,000 |  |  |  | 15,627,000 |
Costs of revenue: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maintenance and supplies |  |  | 613,000 |  |  |  | 518,000 |  |  |  | 1,671,000 |  |  |  | 1,509,000 |
Depreciation and amortization |  |  | 1,666,000 |  |  |  | 1,228,000 |  |  |  | 4,418,000 |  |  |  | 3,812,000 |
Other direct operating costs |  |  | 3,180,000 |  |  |  | 1,095,000 |  |  |  | 6,691,000 |  |  |  | 2,997,000 |
Other direct operating costs, related party |  |  | 170,000 |  |  |  | 191,000 |  |  |  | 510,000 |  |  |  | 781,000 |
|  |  | 5,629,000 |  |  |  | 3,032,000 |  |  |  | 13,290,000 |  |  |  | 9,099,000 |
Gross margin |  |  | 1,370,000 |  |  |  | 2,102,000 |  |  |  | 5,981,000 |  |  |  | 6,528,000 |
Selling and administrative expense |  |  | 1,923,000 |  |  |  | 1,735,000 |  |  |  | 5,698,000 |  |  |  | 5,262,000 |
Interest expense |  |  | 336,000 |  |  |  | 277,000 |  |  |  | 1,070,000 |  |  |  | 825,000 |
Loss on write down of impaired assets and associated removal costs, net |  |  | - |  |  |  | - |  |  |  | 188,000 |  |  |  | 578,000 |
Operating (loss) income |  |  | (889,000 | ) |  |  | 90,000 |  |  |  | (975,000 | ) |  |  | (137,000 | )
Bargain purchase gain RI Acquisition, net of deferred income taxes of $88,000 and $1,314,000 |  |  | 263,000 |  |  |  | - |  |  |  | 3,942,000 |  |  |  | - |
Interest and other income, net |  |  | 47,000 |  |  |  | 135,000 |  |  |  | 212,000 |  |  |  | 318,000 |
(Loss) income before income taxes |  |  | (579,000 | ) |  |  | 225,000 |  |  |  | 3,179,000 |  |  |  | 181,000 |
Income tax (benefit) expense |  |  | (169,000 | ) |  |  | 60,000 |  |  |  | (244,000 | ) |  |  | 93,000 |
Net (loss) income |  |  | (410,000 | ) |  |  | 165,000 |  |  |  | 3,423,000 |  |  |  | 88,000 |
(Less) plus: net loss (income) attributable to non-controlling interests |  |  | 203,000 |  |  |  | (47,000 | ) |  |  | 91,000 |  |  |  | 107,000 |
Net (loss) income attributable to American Shared Hospital Services |  | $ | (207,000 | ) |  | $ | 118,000 |  |  | $ | 3,514,000 |  |  | $ | 195,000 |
Net (loss) income per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
(Loss) income per common share - basic |  | $ | (0.03 | ) |  | $ | 0.02 |  |  | $ | 0.54 |  |  | $ | 0.03 |
(Loss) income per common share - diluted |  | $ | (0.03 | ) |  | $ | 0.02 |  |  | $ | 0.54 |  |  | $ | 0.03 |
Weighted average common shares for basic (loss) earnings per share |  |  | 6,482,000 |  |  |  | 6,366,000 |  |  |  | 6,482,000 |  |  |  | 6,336,000 |
Weighted average common shares for diluted (loss) earnings per share |  |  | 6,482,000 |  |  |  | 6,432,000 |  |  |  | 6,520,000 |  |  |  | 6,406,000 |

See accompanying notes

2

AMERICAN SHARED HOSPITAL SERVICES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(Unaudited)

|  | FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2024 AND 2023 |
|  | Common Shares |  |  | Common Stock |  |  | Additional Paid-in Capital |  |  | Retained Earnings |  |  | Sub-Total ASHS |  |  | Non-controlling Interests in Subsidiaries |  |  | Total |
Balances at January 1, 2023 |  |  | 6,184,000 |  |  | $ | 10,763,000 |  |  | $ | 7,843,000 |  |  | $ | 3,019,000 |  |  | $ | 21,625,000 |  |  | $ | 4,000,000 |  |  | $ | 25,625,000 |
Stock-based compensation expense |  |  | - |  |  |  | - |  |  |  | 96,000 |  |  |  | - |  |  |  | 96,000 |  |  |  | - |  |  |  | 96,000 |
Net income (loss) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 188,000 |  |  |  | 188,000 |  |  |  | (88,000 | ) |  |  | 100,000 |
Balances at March 31, 2023 |  |  | 6,184,000 |  |  |  | 10,763,000 |  |  |  | 7,939,000 |  |  |  | 3,207,000 |  |  |  | 21,909,000 |  |  |  | 3,912,000 |  |  |  | 25,821,000 |
Stock-based compensation expense |  |  | - |  |  |  | - |  |  |  | 97,000 |  |  |  | - |  |  |  | 97,000 |  |  |  | - |  |  |  | 97,000 |
Vested restricted stock awards |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (111,000 | ) |  |  | (111,000 | ) |  |  | (66,000 | ) |  |  | (177,000 | )
Balances at June 30, 2023 |  |  | 6,214,000 |  |  |  | 10,763,000 |  |  |  | 8,036,000 |  |  |  | 3,096,000 |  |  |  | 21,895,000 |  |  |  | 3,846,000 |  |  |  | 25,741,000 |
Stock-based compensation expense |  |  | - |  |  |  | - |  |  |  | 98,000 |  |  |  | - |  |  |  | 98,000 |  |  |  | - |  |  |  | 98,000 |
Vested restricted stock awards |  |  | 56,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Net income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 118,000 |  |  |  | 118,000 |  |  |  | 47,000 |  |  |  | 165,000 |
Balances at September 30, 2023 |  |  | 6,270,000 |  |  | $ | 10,763,000 |  |  | $ | 8,134,000 |  |  | $ | 3,214,000 |  |  | $ | 22,111,000 |  |  | $ | 3,893,000 |  |  | $ | 26,004,000 |
Balances at January 1, 2024 |  |  | 6,300,000 |  |  | $ | 10,763,000 |  |  | $ | 8,232,000 |  |  | $ | 3,629,000 |  |  | $ | 22,624,000 |  |  | $ | 3,655,000 |  |  | $ | 26,279,000 |
Stock-based compensation expense |  |  | - |  |  |  | - |  |  |  | 98,000 |  |  |  | - |  |  |  | 98,000 |  |  |  | - |  |  |  | 98,000 |
Vested restricted stock awards |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Capital contribution non-controlling interests |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 38,000 |  |  |  | 38,000 |
Cash distributions to non-controlling interests |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (95,000 | ) |  |  | (95,000 | )
Net income (loss) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 119,000 |  |  |  | 119,000 |  |  |  | (54,000 | ) |  |  | 65,000 |
Balances at March 31, 2024 |  |  | 6,330,000 |  |  |  | 10,763,000 |  |  |  | 8,330,000 |  |  |  | 3,748,000 |  |  |  | 22,841,000 |  |  |  | 3,544,000 |  |  |  | 26,385,000 |
Stock-based compensation expense |  |  | - |  |  |  | - |  |  |  | 99,000 |  |  |  | - |  |  |  | 99,000 |  |  |  | - |  |  |  | 99,000 |
Vested restricted stock awards |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
RI Acquisition non-controlling interests |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 2,100,000 |  |  |  | 2,100,000 |
Net income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 3,602,000 |  |  |  | 3,602,000 |  |  |  | 166,000 |  |  |  | 3,768,000 |
Balances at June 30, 2024 |  |  | 6,360,000 |  |  |  | 10,763,000 |  |  |  | 8,429,000 |  |  |  | 7,350,000 |  |  |  | 26,542,000 |  |  |  | 5,810,000 |  |  |  | 32,352,000 |
Stock-based compensation expense |  |  | - |  |  |  | - |  |  |  | 88,000 |  |  |  | - |  |  |  | 88,000 |  |  |  | - |  |  |  | 88,000 |
Vested restricted stock awards |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
RI Acquisition non-controlling interests |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (200,000 | ) |  |  | (200,000 | )
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (207,000 | ) |  |  | (207,000 | ) |  |  | (203,000 | ) |  |  | (410,000 | )
Balances at September 30, 2024 |  |  | 6,390,000 |  |  | $ | 10,763,000 |  |  | $ | 8,517,000 |  |  | $ | 7,143,000 |  |  | $ | 26,423,000 |  |  | $ | 5,407,000 |  |  | $ | 31,830,000 |

See accompanying notes

3

AMERICAN SHARED HOSPITAL SERVICES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

|  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Operating activities: |  |  |  |  |  |  |  |
Net income |  | $ | 3,423,000 |  |  | $ | 88,000 |
Adjustments to reconcile net income to net cash from operating activities: |  |  |  |  |  |  |  |
Depreciation, amortization, and other |  |  | 4,501,000 |  |  |  | 3,874,000 |
Loss on write down of impaired assets and associated removal costs, net |  |  | 188,000 |  |  |  | 578,000 |
Accretion of debt issuance costs |  |  | 77,000 |  |  |  | 44,000 |
Bargain purchase gain RI Acquisition, net of deferred income taxes |  |  | (3,942,000 | ) |  |  | - |
Non cash lease expense |  |  | 219,000 |  |  |  | 231,000 |
Accretion of unfavorable lease position |  |  | (26,000 | ) |  |  |  |
Deferred income taxes |  |  | 183,000 |  |  |  | - |
Stock-based compensation expense |  |  | 285,000 |  |  |  | 291,000 |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Receivables |  |  | (3,975,000 | ) |  |  | (498,000 | )
Prepaid expenses and other assets |  |  | 148,000 |  |  |  | 799,000 |
Asset retirement obligations, related party |  |  | (113,000 | ) |  |  | 578,000 |
Related party liabilities |  |  | (2,006,000 | ) |  |  | 2,291,000 |
Accounts payable, accrued liabilities, and deferred revenue |  |  | 2,379,000 |  |  |  | 713,000 |
Income taxes payable |  |  | (1,229,000 | ) |  |  | 54,000 |
Lease liabilities |  |  | (219,000 | ) |  |  | (265,000 | )
Net cash (used in) provided by operating activities |  |  | (107,000 | ) |  |  | 8,778,000 |
Investing activities: |  |  |  |  |  |  |  |
Cash received in excess of cash paid for the RI Acquisition |  |  | 538,000 |  |  |  | - |
Payment for purchases of property and equipment |  |  | (3,278,000 | ) |  |  | (6,176,000 | )
Net cash used in investing activities |  |  | (2,740,000 | ) |  |  | (6,176,000 | )
Financing activities: |  |  |  |  |  |  |  |
Principal payments on long-term debt |  |  | (1,430,000 | ) |  |  | (1,589,000 | )
Payments on line of credit |  |  | (8,900,000 | ) |  |  | - |
Advances on line of credit |  |  | 10,900,000 |  |  |  | 1,400,000 |
Long-term debt financing |  |  | 2,700,000 |  |  |  |  |
Principal payments on short-term financing |  |  | - |  |  |  | (202,000 | )
Capital contribution non-controlling interests |  |  | 38,000 |  |  |  | - |
Distributions to non-controlling interests |  |  | (95,000 | ) |  |  | - |
Debt issuance costs long-term debt |  |  | (97,000 | ) |  |  | (9,000 | )
Net cash provided by (used in) financing activities |  |  | 3,116,000 |  |  |  | (400,000 | )
Net change in cash, cash equivalents, and restricted cash |  |  | 269,000 |  |  |  | 2,202,000 |
Cash, cash equivalents, and restricted cash at beginning of period |  |  | 13,808,000 |  |  |  | 12,453,000 |
Cash, cash equivalents, and restricted cash at end of period |  | $ | 14,077,000 |  |  | $ | 14,655,000 |
Supplemental cash flow disclosure |  |  |  |  |  |  |  |
Cash paid during the period for: |  |  |  |  |  |  |  |
Interest |  | $ | 993,000 |  |  | $ | 781,000 |
Income taxes |  | $ | 1,718,000 |  |  | $ | 277,000 |
Schedule of noncash investing and financing activities |  |  |  |  |  |  |  |
Equipment included in accounts payable and accrued liabilities |  | $ | 3,114,000 |  |  | $ | - |
Non-controlling interest RI Acquisition |  | $ | 1,900,000 |  |  | $ | - |
Detail of cash, cash equivalents and restricted cash at end of period |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 13,827,000 |  |  | $ | 14,537,000 |
Restricted cash |  |  | 250,000 |  |  |  | 118,000 |
Cash, cash equivalents, and restricted cash at end of period |  | $ | 14,077,000 |  |  | $ | 14,655,000 |

See accompanying notes

4

AMERICAN SHARED HOSPITAL SERVICES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Basis of Presentation

In the opinion of the management of American Shared Hospital Services (“ASHS”), the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary for the fair presentation of ASHS consolidated financial position as of September 30, 2024, the results of its operations for the three and nine-month periods ended September 30, 2024 and 2023, and the cash flows for the nine-month periods ended September 30, 2024 and 2023. The results of operations for the three and nine-month periods ended September 30, 2024 are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2023 have been derived from the audited consolidated financial statements.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2023 included in the ASHS Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 1, 2024.

These condensed consolidated financial statements include the accounts of ASHS and its subsidiaries (the “Company”) including as follows: ASHS wholly owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), PBRT Orlando, LLC (“Orlando”), ASHS-Mexico, S.A. de C.V. (“ASHS-Mexico”), ASHS-Rhode Island Proton Beam Radiation Therapy, LLC, ASHS-Bristol Radiation Therapy, LLC, OR21, Inc., and MedLeader.com, Inc. (“MedLeader”); ASHS is the majority owner of Southern New England Regional Cancer Center (“SNERCC”), Roger Williams Radiation Therapy, LLC (“RWRT”) and Long Beach Equipment, LLC (“LBE”); ASRS is the majority-owner of GK Financing, LLC (“GKF”), which wholly owns the subsidiaries Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”) and HoldCo GKC S.A. (“HoldCo”). HoldCo wholly owns the subsidiary Gamma Knife Center Ecuador S.A. (“GKCE”). ASHS-Mexico is the majority owner of AB Radiocirugia y Radioterapia de Puebla, S.A.P.I. de C.V. of Puebla (“Puebla”). GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”).

The Company (through ASRS) and Elekta AB (“Elekta”), the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GKF. As of September 30, 2024, GKF provides Gamma Knife units to ten medical centers in the United States in the states of Florida, Illinois, Indiana, Mississippi, Nebraska, New Mexico, New York, Ohio, Oregon, and Texas. GKF also owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States.

On November 10, 2023, the Company entered into an Investment Purchase Agreement (the “IPA”) with GenesisCare USA, Inc. (the “GenesisCare”) and GenesisCare USA Holdings, Inc. (“GC Holdings”), pursuant to which GenesisCare agreed to sell to the Company its entire equity interest in each of SNERCC and RWRT, (collectively, the “RI Companies”) and to assign certain payor contacts to the Company for a purchase price of $2,850,000 (such transaction, the “RI Acquisition”). The equity interests acquired by the Company under the IPA equates to a 60% interest in each RI Target Company. The RI Companies operate three functional radiation therapy cancer centers in Rhode Island. The parties completed the remaining closing conditions pursuant to the IPA and closed the RI Acquisition on May 7, 2024. Accordingly, activity from May 7, 2024 forward is included in the condensed consolidated financial statements. See Note 11 - Rhode Island Acquisition to the condensed consolidated financial statements for further information.

On June 28, 2024, ASHS-Mexico, S.A.P.I. de C.V. signed a Joint Venture Agreement with Hospital San Javier, S.A. de C.V. (“HSJ”) to establish Newco to treat public- and private-paying cancer patients and provide radiosurgery services in Guadalajara, Mexico. The Company and HSJ will hold 70% and 30% ownership interests, respectively, in Newco. Under the agreement, the Company is responsible for upgrading HSJ’s existing Gamma Knife Perfexion system to a Gamma Knife Esprit and paying 50% of all site modification costs required to install the Esprit. The Company does not expect that Newco will begin treating patients until the first half of 2025.

On April 27, 2022, the Company signed a Joint Venture Agreement with the principal owners of Guadalupe Amor y Bien S.A. de C.V. (“Guadalupe”) to establish Puebla to treat public- and private-paying cancer patients and provide radiation therapy and radiosurgery services in Guadalupe, Mexico. The Company and Guadalupe hold 85% and 15% ownership interests, respectively, in Puebla. Under the agreement, the Company is responsible for providing a linear accelerator upgrade to an Elekta Versa HD, and Guadalupe will be accountable for all site modification costs. The Company formed ASHS-Mexico on October 3, 2022 to establish Puebla. Puebla was formed on December 15, 2022 and began treating patients in July 2024. Operating costs incurred during the three and nine-month periods ended September 30, 2024 by Puebla, are included in the condensed consolidated statement of operations.

The Company formed the subsidiaries GKPeru, Puebla, and acquired GKCE for the purposes of expanding its business internationally; Orlando and LBE to provide PBRT equipment and services in Orlando, Florida and Long Beach, California, respectively; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. LBE is not expected to generate revenue within the next two years.

The Company continues to develop its design and business model for The Operating Room for the 21st CenturySM through its 50%-owned subsidiary OR21, LLC (“OR21 LLC”). The remaining 50% is owned by an architectural design company. OR21 LLC is not expected to generate significant revenue for at least the next two years.

MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is not operational at this time.

All significant intercompany accounts and transactions have been eliminated in consolidation.

5

Accounting pronouncements issued and not yet adopted - In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) which enhances the disclosure requirements for segment reporting, primarily disclosures around significant segment expenses. The key provisions of the amendments require disclosure of significant segment expense reviewed by the Chief Operating Decision Maker (the “CODM”), require disclosure of an “other” segment category, require disclosure of segment profit or loss and assets for interim periods, clarify and require disclosure of other measurements used by the CODM in assessing segment performance and allocating resources, and require disclosure of the CODM’s title and position and an explanation of how the CODM assesses segment performance. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating ASU 2023-07 to determine the impact it may have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures (“ASU 2023-09”) which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company is currently evaluating ASU 2023-09 to determine the impact it may have on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (“ASU 2024-03”) which requires entities to 1. disclose amounts of (a) purchase of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and, (e) depreciation, depletion, and amortization recognized as part of oil-and gas-producing activities, 2. include certain amounts that are already required to be disclosed under current Generally Accepted Accounting Principles in the same disclosures as other disaggregation requirements, 3. disclose a qualitative description of the amounts remaining in relevant expense captions that are not necessarily disaggregated quantitatively, and 4. disclose the total amount of selling expenses, in annual reporting periods, an entity’s definition of selling expense. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating ASU 2024-03 to determine the impact it may have on its consolidated financial statements.

Revenue recognition - The Company recognizes revenues under Accounting Standards Codification (“ASC”) 842 Leases (“ASC 842”) and ASC 606 Revenue from Contracts with Customers (“ASC 606”).

Rental revenue from medical equipment leasing (“leasing”) – The Company recognizes revenues under ASC 842 when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s lease contracts typically have a ten-year term and are classified as either fee per use or revenue sharing. Fee per use revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company’s revenue sharing arrangements also have a cost sharing component and net profit share for the operating costs of the center. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs and profit. The operating costs and estimated net operating profit are recorded as other direct operating costs in the condensed consolidated statements of operations. For the three and nine-month periods ended September 30, 2024, the Company recognized leasing revenue of approximately $3,312,000 and $11,464,000 compared to $3,946,000 and $12,987,000 for the same periods in the prior year, respectively. Of the ASC 842 revenue, for the three and nine-month periods ended September 30, 2024, approximately $2,316,000 and $7,386,000 were for PBRT services, compared to $2,219,000 and $7,078,000 for the same periods in the prior year, respectively.

Direct patient services income (“retail”) – The Company has stand-alone facilities in Lima, Peru, Guayaquil, Ecuador, and Puebla, Mexico where contracts exist between the Company’s facilities and the individual patients treated at the facility. Under ASC 606, the Company acts as the principal in these transactions and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife or radiation therapy treatment. Revenue related to these treatments is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru’s payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. GKCE’s patient population is primarily covered by a government payor and payments are paid between three and six months following issuance of an invoice. The facility in Puebla currently has a contract with one local hospital to cover its eligible patient base and is also treating self-pay patients. Puebla’s payment terms are typically prepaid for self-pay patients and net 30 days for the hospital patients. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts.

On May 7, 2024, the Company acquired 60% of the interests of the RI Companies. The RI Companies operate three, existing, stand-alone radiation therapy cancer centers in Woonsocket, Warwick and Providence, Rhode Island, where contracts exist between the Company’s facilities and the individual patients treated at the facility. Under ASC 606, the Company acts as the principal in these transactions and provides, at a point in time, a single performance obligation, in the form of radiation therapy treatment. Revenue related to radiation therapy is recognized at the expected amount to be received, based on insurance contracts and payor mix, when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. Payment terms at these facilities are typically prepaid for self-pay patients and insurance providers are paid net 30 to 60 days. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts. The Company also concluded the three facilities are part of its retail segment, see further discussion below.

Accounts receivable balances under ASC 606 at September 30, 2024 and January 1, 2024 were $5,357,000 and $1,626,000, respectively. Accounts receivable balances under ASC 606 at September 30, 2023 and January 1, 2023 were $1,416,000 and $1,118,000, respectively. For the three and nine-month periods ended September 30, 2024, the Company recognized retail revenues of approximately $3,687,000 and $7,807,000 compared to $988,000 and $2,440,000 for the same periods in the prior year, respectively.

Business Combinations - Business combinations are accounted for under ASC 805 Business Combinations (“ASC 805”) using the acquisition method of accounting. Under the acquisition method of accounting, all assets acquired, identifiable intangible assets, liabilities assumed and applicable non-controlling interests are recognized at fair value as of the acquisition date. Costs incurred associated with the acquisition of a business are expensed as incurred. The allocation of purchase price requires management to make significant estimates and assumptions, especially with respect to tangible assets, any intangible assets identified and non-controlling interests. These estimates include, but are not limited to, a market participant’s expectation of future cash flows from acquired customers, acquired trade names, useful lives of acquired assets, and discount rates. See Note 11 - Rhode Island Acquisition to the condensed consolidated financial statements for further discussion on acquisitions.

6

Business segment information - Based on the guidance provided in accordance with ASC 280 Segment Reporting (“ASC 280”), the Company analyzed its subsidiaries which are all in the business of providing radiosurgery and radiation therapy services, either through leasing to healthcare providers or directly to patients, and concluded there are two reportable segments, leasing and retail. As of September 30, 2024, the Company provided Gamma Knife and PBRT equipment to eleven hospitals in the United States, which constitutes the leasing segment. As of September 30, 2024, the Company owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador, one single-unit radiation therapy facility in Puebla, Mexico, and following the RI Acquisition on May 7, 2024, the Company also owns and operates three single-unit radiation therapy facilities in Rhode Island, which collectively constitute the retail segment. An operating segment is defined by ASC 280 as a component of an entity that engages in business activities in which it may recognize revenues and incur expenses, that has operating results that are regularly reviewed by the Company’s Chief Operating Decision Maker (“CODM”), and for which its discrete financial information is available. The Company determined two reportable segments existed due to similarities in economics of business operations and how the Company recognizes revenue for the patient treatment. The operating results of the two reportable segments are reviewed by the Company’s Executive Chairman of the Board and Chief Executive Officer, who is also the CODM.

The revenues, depreciation, interest expense, interest income, tax expense and net income attributable to American Shared Hospital Services for the Company’s two reportable segments as of September 30, 2024 and 2023 consist of the following:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Leasing (includes equipment sales, net) |  | $ | 3,312,000 |  |  | $ | 4,146,000 |  |  | $ | 11,464,000 |  |  | $ | 13,187,000 |
Retail |  |  | 3,687,000 |  |  |  | 988,000 |  |  |  | 7,807,000 |  |  |  | 2,440,000 |
Total |  | $ | 6,999,000 |  |  | $ | 5,134,000 |  |  | $ | 19,271,000 |  |  | $ | 15,627,000 |

|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Depreciation expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Leasing |  | $ | 1,101,000 |  |  | $ | 1,088,000 |  |  | $ | 3,412,000 |  |  | $ | 3,341,000 |
Retail |  |  | 543,000 |  |  |  | 177,000 |  |  |  | 1,089,000 |  |  |  | 533,000 |
Total |  | $ | 1,644,000 |  |  | $ | 1,265,000 |  |  | $ | 4,501,000 |  |  | $ | 3,874,000 |

|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Leasing |  | $ | 304,000 |  |  | $ | 277,000 |  |  | $ | 972,000 |  |  | $ | 825,000 |
Retail |  |  | 32,000 |  |  |  | - |  |  |  | 98,000 |  |  |  | - |
Total |  | $ | 336,000 |  |  | $ | 277,000 |  |  | $ | 1,070,000 |  |  | $ | 825,000 |

|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Leasing |  | $ | 57,000 |  |  | $ | 149,000 |  |  | $ | 246,000 |  |  | $ | 346,000 |
Retail |  |  | 6,000 |  |  |  | - |  |  |  | 6,000 |  |  |  | - |
Total |  | $ | 63,000 |  |  | $ | 149,000 |  |  | $ | 252,000 |  |  | $ | 346,000 |

|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Income tax (benefit) expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Leasing |  | $ | (276,000 | ) |  | $ | 21,000 |  |  | $ | (415,000 | ) |  | $ | 34,000 |
Retail |  |  | 107,000 |  |  |  | 39,000 |  |  |  | 171,000 |  |  |  | 59,000 |
Total |  | $ | (169,000 | ) |  | $ | 60,000 |  |  | $ | (244,000 | ) |  | $ | 93,000 |

|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net (loss) income attributable to American Shared Hospital Services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Leasing |  | $ | (602,000 | ) |  | $ | 100,000 |  |  | $ | (2,096,000 | ) |  | $ | 328,000 |
Retail |  |  | 395,000 |  |  |  | 18,000 |  |  |  | 5,610,000 |  |  |  | (133,000 | )
Total |  | $ | (207,000 | ) |  | $ | 118,000 |  |  | $ | 3,514,000 |  |  | $ | 195,000 |

Reclassifications - Certain comparative balances as of September 30, 2023 and December 31, 2023 have been reclassified to make them consistent with the current year presentation.

7

Note 2. Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife equipment, LINAC units and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally between three and ten years, and after accounting for salvage value on the equipment where indicated. The Company determines salvage value based on the estimated fair value of the equipment at the end of its useful life.

Depreciation for PBRT equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years.

The following table summarizes property and equipment as of September 30, 2024 and December 31, 2023:

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Medical equipment and facilities |  | $ | 78,981,000 |  |  | $ | 77,150,000 |
Office equipment |  |  | 490,000 |  |  |  | 306,000 |
Construction in progress |  |  | 1,221,000 |  |  |  | 3,771,000 |
|  |  | 80,692,000 |  |  |  | 81,227,000 |
Accumulated depreciation |  |  | (45,885,000 | ) |  |  | (55,383,000 | )
Net property and equipment |  | $ | 34,807,000 |  |  | $ | 25,844,000 |
Net property and equipment held outside of the United States |  | $ | 5,934,000 |  |  | $ | 6,174,000 |

Depreciation expense in the condensed consolidated statements of operations for the three and nine-month periods ended September 30, 2024 and 2023 is as follows:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Depreciation expense |  | $ | 1,644,000 |  |  | $ | 1,265,000 |  |  | $ | 4,501,000 |  |  | $ | 3,874,000 |

Note 3. Long-Term Debt Financing

On April 9, 2021 the Company along with certain of its domestic subsidiaries (collectively, the “Loan Parties”) entered into a five year $22,000,000 credit agreement (the “Credit Agreement”) with Fifth Third Bank, N.A. (“Fifth Third”). The Credit Agreement includes three loan facilities. The first loan facility is a $9,500,000 term loan (the “Term Loan”) which was used to refinance the domestic Gamma Knife debt and finance leases, and associated closing costs. The second loan facility of $5,500,000 is a delayed draw term loan (the “DDTL”) which was used to refinance the Company’s PBRT finance leases and associated closing costs, as well as to provide additional working capital. The third loan facility provides for a $7,000,000 revolving line of credit (the “Revolving Line”) available for future projects and general corporate purposes. The Company borrowed $4,500,000 on the Revolving Line as of September 30, 2024. The facilities have a five-year maturity and carry a floating interest of based on the Secured Overnight Financing Rate (“SOFR”) plus 3.0% and are secured by a lien on substantially all of the assets of the Loan Parties and guaranteed by ASHS.

On January 25, 2024 (the “First Amendment Effective Date”), the Company and Fifth Third entered into a First Amendment to Credit Agreement (the “First Amendment”), which amended the Credit Agreement to add a new term loan in the aggregate principal amount of $2,700,000 (the “Supplemental Term Loan”). The proceeds of the Supplemental Term Loan were advanced in a single borrowing on January 25, 2024, and were used for capital expenditures related to the Company’s operations in Puebla, Mexico and other related transaction costs. The Supplemental Term Loan will mature on January 25, 2030 (the “Maturity Date”). Interest on the Supplemental Term Loan is payable monthly during the initial twelve month period following the First Amendment Effective Date. Following such twelve month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Supplemental Term Loan by the Maturity Date. The Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. The First Amendment also replaces the LIBOR-based rates in the Credit Agreement with SOFR-based rates. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%. The long-term debt on the condensed consolidated balance sheets related to the Term Loan and DDTL was $12,588,000 and $10,825,000 as of September 30, 2024 and December 31, 2023, respectively. The Company capitalized debt issuance costs of $97,000 as of September 30, 2024 related to issuance of the Supplemental Term Loan.

The Credit Agreement contains customary covenants and representations, including without limitation, a minimum fixed charge coverage ratio of 1.25 and maximum funded debt to EBITDA ratio of 3.0 to 1.0 (tested on a trailing twelve-month basis at the end of each fiscal quarter), reporting obligations, limitations on dispositions, changes in ownership, mergers and acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and capital expenditures. The Loan Parties are in compliance with the Credit Agreement covenants as of September 30, 2024.

8

The loan entered into with United States International Development Finance Corporation (“DFC”) in connection with the acquisition of GKCE in June 2020 (the “DFC Loan”) was obtained through the Company’s wholly-owned subsidiary, HoldCo and is guaranteed by GKF. The DFC Loan is secured by a lien on GKCE’s assets. The first tranche of the DFC Loan was funded in June 2020. During the fourth quarter of 2023, the second tranche of the DFC loan was funded to finance the equipment upgrade in Ecuador. The amount outstanding under the first tranche of the DFC Loan is payable in 29 quarterly installments with a fixed interest rate of 3.67%. The amount outstanding under the second tranche of the DFC Loan is payable in 16 quarterly installments with a fixed interest rate of 7.49%. The long-term debt on the condensed consolidated balance sheets related to the DFC Loan was $1,970,000 and $2,464,000 as of September 30, 2024 and December 31, 2023, respectively. The Company capitalized debt issuance costs of $0 and $9,000 as of September 30, 2024 and December 31, 2023, respectively, related to maintenance and administrative fees on the DFC Loan.

The DFC Loan contains customary covenants including without limitation, requirements that HoldCo maintain certain financial ratios related to liquidity and cash flow as well as depository requirements. On March 28, 2024 the HoldCo received a waiver and amendment from DFC for certain covenants as of December 31, 2023 and through December 31, 2024 and amended other covenants and definitions permanently. HoldCo was in compliance with all debt covenants pursuant to the DFC Loan as amended and waived at September 30, 2024.

The accretion of debt issuance costs for the three and nine-month periods ended September 30, 2024 was $19,000 and $77,000 compared to $7,000 and $44,000 for the same periods in the prior year, respectively. As of September 30, 2024 and December 31, 2023, the unamortized deferred issuance costs on the consolidated balance sheet was $184,000 and $164,000, respectively.

As of September 30, 2024, long-term debt on the condensed consolidated balance sheets was $14,375,000. The following are contractual maturities of long-term debt as of September 30, 2024, excluding deferred issuance costs of $184,000:

Year ending December 31, |  | Principal |
2024 (excluding the nine-months ended September 30, 2024) |  | $ | 727,000 |
2025 |  |  | 3,402,000 |
2026 |  |  | 8,272,000 |
2027 |  |  | 1,033,000 |
2028 |  |  | 540,000 |
Thereafter |  |  | 585,000 |
|  | $ | 14,559,000 |

Note 4. Other Accrued Liabilities

Other accrued liabilities consist of the following as of September 30, 2024 and December 31, 2023:

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Professional services |  | $ | 254,000 |  |  | $ | 472,000 |
Operating costs |  |  | 943,000 |  |  |  | 450,000 |
Other |  |  | 769,000 |  |  |  | 304,000 |
Total other accrued liabilities |  | $ | 1,966,000 |  |  | $ | 1,226,000 |

Note 5. Leases

The Company determines if a contract is a lease at inception. Under ASC 842, the Company is a lessor of equipment to various customers. Leases that commenced prior to the ASC 842 adoption date were classified as operating leases under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. All of the Company’s lessor arrangements entered into or modified after ASC 842 adoption are also classified as operating leases. Some of these lease terms have an option to extend the lease after the initial term, but do not contain the option to terminate early or purchase the asset at the end of the term. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities that arise from short-term (12 months or less) leases for any class of underlying asset.

The Company’s Gamma Knife and PBRT contracts with hospitals are classified as operating leases under ASC 842. The related equipment is included in medical equipment and facilities on the Company’s condensed consolidated balance sheets. As all income from the Company’s lessor arrangements is solely based on procedure volume, all income is considered variable payments not dependent on an index or a rate. As such, the Company does not measure future operating lease receivables.

On November 3, 2021, the Company entered into an agreement to sublease (the “Sublease”) its corporate office located at Two Embarcadero Center, Suite 410, San Francisco, California, where it leased approximately 3,253 square feet for $22,011 per month and the lease expired in August 2023. The Sublease was for $16,195 per month through the contract expiration date. The Company also entered into a lease agreement (the “Lease”) for new corporate office space at 601 Montgomery St., Suite 1112, San Francisco, CA for approximately 900 square feet for $4,500 per month with a lease expiration date in November 2024. The Company did not renew this lease.

On May 7, 2024, the Company completed the RI Acquisition and acquired 60% of the equity interests of the RI Companies. The RI Companies operate three single-unit LINAC facilities. The Company assessed the existing lease agreements under ASC 842 and concluded two of the three facilities contained operating leases. The Company included these leases in its presentation of the condensed consolidated financial statements for the three and nine-month periods ended September 30, 2024. The Company’s operating lease in Woonsocket is with a related party and contains a sublease for a 1,950 square feet of the clinic space. The sublease is also with a related party. Sublease income, related party, for the three and nine-month periods ended September 30, 2024 was $15,000 and $24,000, respectively. Rent payable to related parties was approximately $184,000 as of September 30, 2024.

9

The Company’s lessee operating leases are accounted for as ROU assets, current portion of lease liabilities, and lease liabilities on the condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The Company’s operating lease contracts do not provide an implicit rate for calculating the present value of future lease payments. The Company determined its incremental borrowing rate to be in the range of approximately 4% and 8% by using available market rates and expected lease terms. The operating lease ROU assets and liabilities include any lease payments made and there were no lease incentives or initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company’s lessee operating lease agreements are for administrative office space and related equipment and two of its recently acquired stand-alone facilities in Rhode Island. These leases have remaining lease terms of approximately 5 to 17 years, some of which include options to renew or extend the lease. As of September 30, 2024, operating ROU assets, net of unfavorable leasehold interests were $986,000, and lease liabilities were $1,735,000.

The following table summarizes the maturities of the Company's lessee operating lease liabilities as of September 30, 2024:

Year ending December 31, |  | Operating Leases |
2024 (excluding the nine-months ended September 30, 2024) |  | $ | 109,000 |
2025 |  |  | 346,000 |
2026 |  |  | 347,000 |
2027 |  |  | 347,000 |
2028 |  |  | 348,000 |
Thereafter |  |  | 958,000 |
Total lease payments |  |  | 2,455,000 |
Less imputed interest |  |  | (720,000 | )
Total |  | $ | 1,735,000 |

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Lease cost |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease cost |  | $ | 133,000 |  |  | $ | 59,000 |  |  | $ | 219,000 |  |  | $ | 265,000 |
Sublease income, related party |  |  | (15,000 | ) |  |  | (30,000 | ) |  |  | (24,000 | ) |  |  | (129,000 | )
Total lease cost |  | $ | 118,000 |  |  | $ | 29,000 |  |  | $ | 195,000 |  |  | $ | 136,000 |
Other information |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash paid for amounts included in the measurement of lease liabilities - Operating leases |  | $ | 133,000 |  |  | $ | 59,000 |  |  | $ | 219,000 |  |  | $ | 265,000 |
Weighted-average remaining lease term - Operating leases in years |  |  | 7.85 |  |  |  | 0.89 |  |  |  | 7.85 |  |  |  | 0.89 |
Weighted-average discount rate - Operating leases |  |  | 8.00 | % |  |  | 4.99 | % |  |  | 8.00 | % |  |  | 4.99 | %

Note 6. Per Share Amounts

Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. The Company calculates diluted shares using the treasury stock method. Because the Company reported a loss for the three-month period ended September 30, 2024, the potentially dilutive effects of approximately 62,000 of the Company’s stock options and 33,000 of the Company’s unvested restricted stock awards were not considered for the reporting period. The computation for the nine-month period ended September 30, 2024 excluded approximately 4,000 of the Company’s stock options because the exercise price of the options was higher than the average market price during the periods. The computation for the three and nine-month periods ended September 30, 2023 excluded approximately 118,000 and 91,000 of the Company’s stock options because the price of the options was higher than the average market price during the period. The weighted average common shares outstanding for basic earnings per share for the three and nine-month periods ended September 30, 2024 and 2023 included approximately 123,000 and 123,000, respectively, of the Company's restricted stock awards that are fully vested but are deferred for issuance.

The following table sets forth the computation of basic and diluted earnings per share for the three and nine-month periods ended September 30, 2024 and 2023:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net (loss) income attributable to American Shared Hospital Services |  | $ | (207,000 | ) |  | $ | 118,000 |  |  | $ | 3,514,000 |  |  | $ | 195,000 |
Weighted average common shares for basic (loss) earnings per share |  |  | 6,482,000 |  |  |  | 6,366,000 |  |  |  | 6,482,000 |  |  |  | 6,336,000 |
Dilutive effect of stock options and restricted stock awards |  |  | - |  |  |  | 66,000 |  |  |  | 38,000 |  |  |  | 70,000 |
Weighted average common shares for diluted (loss) earnings per share |  |  | 6,482,000 |  |  |  | 6,432,000 |  |  |  | 6,520,000 |  |  |  | 6,406,000 |
Basic (loss) earnings per share |  | $ | (0.03 | ) |  | $ | 0.02 |  |  | $ | 0.54 |  |  | $ | 0.03 |
Diluted (loss) earnings per share |  | $ | (0.03 | ) |  | $ | 0.02 |  |  | $ | 0.54 |  |  | $ | 0.03 |

10

Note 7. Stock-based Compensation

In June 2021, the Company’s shareholders approved an amendment and restatement of the Company’s Incentive Compensation Plan (the “Plan”), that among other things, increased the number of shares of the Company’s common stock reserved for issuance under the Plan to 2,580,000 and extended the term of the Plan by five years to February 22, 2027. The Plan provides that the shares reserved under the Plan are available for issuance to officers of the Company, other key employees, non-employee directors, and advisors. No further grants or share issuances will be made under the previous plans.

Stock-based compensation expense associated with the Company’s stock options to employees is calculated using the Black-Scholes valuation model. The Company’s stock awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimates. The estimated fair value of the Company’s option grants is estimated using assumptions for expected life, volatility, dividend yield, and risk-free interest rate which are specific to each award. The estimated fair value of the Company’s options is expensed over the period during which an employee is required to provide service in exchange for the award (requisite service period), usually the vesting period. Accordingly, stock-based compensation cost before income tax effect for the Company’s options and restricted stock awards in the amount of $88,000 and $285,000 for the three and nine-month periods ended September 30, 2024 and $98,000 and $291,000 for the three and nine-month periods ended September 30, 2023, respectively, is reflected in selling and administrative expense in the condensed consolidated statements of operations. For the nine-month period ended September 30, 2024, there was approximately $26,000 of unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under the Plan. This cost is expected to be recognized over a period of approximately three years.

The following table summarizes stock option activity for the nine-month periods ended September 30, 2024 and 2023:

|  | Stock Options |  |  | Grant Date Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Life (in Years) |  |  | Intrinsic Value |
Outstanding at January 1, 2024 |  |  | 146,000 |  |  | $ | 2.83 |  |  |  | 5.44 |  |  | $ | - |
Forfeited |  |  | (84,000 | ) |  | $ | 2.87 |  |  |  | - |  |  | $ | - |
Outstanding at September 30, 2024 |  |  | 62,000 |  |  | $ | 2.76 |  |  |  | 2.56 |  |  | $ | 20,000 |
Exercisable at September 30, 2024 |  |  | 35,000 |  |  | $ | 2.76 |  |  |  | 1.32 |  |  | $ | - |
Outstanding at January 1, 2023 |  |  | 95,000 |  |  | $ | 2.76 |  |  |  | 4.83 |  |  | $ | 25,000 |
Granted |  |  | 70,000 |  |  | $ | 2.82 |  |  |  | 7.00 |  |  | $ | - |
Forfeited |  |  | (19,000 | ) |  | $ | 2.69 |  |  |  | - |  |  | $ | - |
Outstanding at September 30, 2023 |  |  | 146,000 |  |  | $ | 2.80 |  |  |  | 5.51 |  |  | $ | - |
Exercisable at September 30, 2023 |  |  | 38,000 |  |  | $ | 2.86 |  |  |  | 3.35 |  |  | $ | - |

Note 8. Income Taxes

The Company generally calculates its effective income tax rate at the end of an interim period using an estimate of the annualized effective income tax rate expected to be applicable for the full fiscal year. However, when a reliable estimate of the annualized effective income tax rate cannot be made, the Company computes its provision for income taxes using the actual effective income tax rate for the results of operations reported within the year-to-date periods. The Company’s effective income tax rate is highly influenced by relative income or losses reported and the amount of the nondeductible stock-based compensation associated with grants of its common stock options and from the results of international operations. A small change in estimated annual pretax income can produce a significant variance in the annualized effective income tax rate given the expected amount of these items. As a result, the Company has computed its provision for income taxes for the three and nine-month periods ended September 30, 2024 and 2023 by applying the actual effective tax rates to income or reported within the condensed consolidated financial statements through those periods. The provision for income taxes for the nine-month period ended September 30, 2024 included a non-recurring adjustment for unrecognized tax benefits related to foreign taxes of $100,000 which offset income tax expense for the same period.

Note 9. Commitments

As of September 30, 2024, the Company had commitments to purchase and install four Leksell Gamma Knife Esprit Systems (“Esprit”), one Gamma Plan workstation, and two Linear Accelerator (“LINAC”) systems. One LINAC and one Esprit will be placed at future customer sites. The remaining Esprit upgrades and LINACs are scheduled to occur during 2025 or later at existing customer sites. Total Gamma Knife and LINAC commitments as of September 30, 2024 were $13,383,000. There are no deposits on the condensed consolidated balance sheets related to these commitments as of September 30, 2024. It is the Company’s intent to finance substantially all of these commitments. There can be no assurance that financing will be available for the Company’s current or future projects, or at terms that are acceptable to the Company. However, the Company currently has cash on hand of $14,077,000 and its Revolving Line of $7,000,000 and is actively engaged with financing resources to fund these projects. The Company borrowed $4,500,000 on the Revolving Line as of September 30, 2024.

On September 4, 2022, the Company entered into a Maintenance and Support Agreement with Mevion Medical Systems, Inc. (“Mevion”), which provides for maintenance and support of the Company’s PBRT unit at Orlando Health from September 2022 through April 2026. The agreement requires the Company to make an annual prepayment of $1,939,000 for the current contractual period ( one year). As of September 30, 2024, half of the prepayment was recorded as a prepaid contract and is being amortized over the one-year service period.

As of September 30, 2024, the Company had commitments to service and maintain its Gamma Knife, LINAC, and PBRT equipment. The service commitments are carried out via contracts with Mevion, Elekta and Mobius Imaging, LLC. The Company’s commitment to purchase one LINAC system also includes a 5-year agreement to service the equipment, respectively. Total service commitments as of September 30, 2024 were $13,712,000. The Gamma Knife and certain other service contracts are paid monthly, as service is performed. The Company believes that cash flow from cash on hand and operations will be sufficient to cover these payments.

11

Note 10. Related Party Transactions and Balances

The Company’s Gamma Knife business is operated through its 81% indirect interest in its GKF subsidiary. The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife. Since the Company purchases its Gamma Knife units from Elekta, there are significant related party transactions with Elekta, such as equipment purchases, commitments to purchase and service equipment, and costs to maintain the equipment. The Company’s operating lease in Woonsocket, Rhode Island is with a related party. See Note 5 - Leases to the condensed consolidated financial statements for further discussion.

The following table summarizes related party activity for the three and nine-month periods ended September 30, 2024 and 2023:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Equipment purchases and de-install costs |  | $ | 524,000 |  |  | $ | 2,147,000 |  |  | $ | 3,461,000 |  |  | $ | 3,565,000 |
Costs incurred to maintain equipment |  |  | 170,000 |  |  |  | 191,000 |  |  |  | 510,000 |  |  |  | 781,000 |
Total related party transactions |  | $ | 694,000 |  |  | $ | 2,338,000 |  |  | $ | 3,971,000 |  |  | $ | 4,346,000 |

The Company also had commitments to purchase and install four Esprit units, purchase two LINACs, and service the related equipment of $19,068,000 as of September 30, 2024.

Related party liabilities on the condensed consolidated balance sheets consist of the following as of September 30, 2024 and December 31, 2023

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Accounts payable, asset retirement obligation and other accrued liabilities |  | $ | 4,138,000 |  |  | $ | 2,361,000 |

Note 11. Rhode Island Acquisition

On November 10, 2023, the Company entered into the IPA with GenesisCare and GC Holdings, pursuant to which GenesisCare agreed to sell to the Company its entire equity interest in each of the RI Companies and to assign certain payor contacts to the Company for a cash purchase price of $2,850,000 (such transaction, the “RI Acquisition”). The equity interests acquired by the Company under the IPA equates to a 60% interest in each RI Company. The RI Companies operate three functional radiation therapy cancer centers in Rhode Island. The Company acquired the RI Companies to expand its growing retail business model in the United States and continue to diversify its cancer treatment product offerings.

On March 1, 2024, the Company, GenesisCare and GC Holdings entered into a First Amendment to the Investment Agreement pursuant to which the parties agreed to extend the date on which a party could terminate the IPA if the closing conditions had not been met (the “Permitted Termination Date”) from March 10, 2024 to April 30, 2024. On April 18, 2024, the parties agreed to a Second Amendment to the Investment Agreement pursuant to which GenesisCare agreed to sell a GE Discovery RT CT Simulator (“CT Sim”) to the Company for $175,000, payment for which was required 5 days following the close of the acquisition. On April 24 2024, the Company, GenesisCare and GC Holdings, entered into a Third Amendment to the Investment Agreement that further extended the Permitted Termination Date to May 31, 2024. On May 7, 2024, the parties entered into a Fourth Amendment to the Investment Purchase Agreement, pursuant to which GenesisCare agreed to transfer certain assets and payor contracts to the RI Companies, rather than transferring such assets and payor contracts to the Company. The parties completed the remaining closing conditions pursuant to the IPA and closed the RI Acquisition on May 7, 2024 (the “Closing Date”).

The RI acquisition has been accounted for as a business combination under ASC 805, which requires, among other things, that purchase consideration, assets acquired, liabilities assumed and non-controlling interest be measured at their fair values as of the acquisition date. The allocation of purchase price considerations is preliminary, and is subject to revision as more detailed analyses are completed and additional information about the fair value of assets acquired and liabilities assumed becomes available. During the measurement period, which can be no more than one year from the Closing Date, the Company expects to continue to obtain information to assist in determining the final fair value of assets acquired. The assets acquired were recorded based on valuations derived from estimated fair value assessments and assumptions used by the Company. Thus, the provisional measurements of fair value discussed below are subject to change. The Company expects to finalize the valuations as soon as practicable, but no later than one year from the Closing Date. While the Company believes its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired, and the resulting amount of the bargain purchase gain. During the three-month period ended September 30, 2024, the Company concluded some of the fair value estimates for accounts receivable, non-controlling interests, and unfavorable leasehold interests required adjustment. The adjusted preliminary allocations provided below reflect these changes.

The Company recorded medical equipment, facilities and non-controlling interest at fair value as of the Closing Date. Sales comparison and cost approaches were used to value the medical equipment, including assumptions of estimated direct costs associated with acquiring the equipment. Where appropriate, adjustments were made to the direct replacement cost to reflect depreciation and obsolescence. The sales comparison approach was also utilized to value certain assets, involving secondary market research. The cost approach was also used to value the facilities acquired and the unfavorable leasehold interest. The non-controlling interest was recorded at fair value based on the purchase price paid for the acquisition, after any premium or discount derived from the operating agreement with the minority owners.

12

The Company recorded a preliminary allocation of the purchase price consideration as of the Closing Date, for the three-month period ended June 30, 2024. During the three-month period ended September 30, 2024, the Company concluded some of the fair value estimates for accounts receivable, non-controlling interests, and unfavorable leasehold interests required adjustment. The net effect of these changes was an increase to the bargain purchase gain of $263,000, net of deferred taxes of $88,000. The net impact to the condensed consolidated statement of operations, outside of the change in the bargain purchase gain, was not material for the three and nine-month periods ended September 30, 2024.

The major classes of assets and liabilities to which the Company has preliminarily allocated the fair value of the purchase price consideration as of September 30, 2024 were as follows:

|  | May 7, 2024 |  |  | Remeasurement |  |  | September 30, 2024 |
Cash and cash equivalents |  | $ | 3,388,000 |  |  | $ | - |  |  | $ | 3,388,000 |
Accounts receivable |  |  | 919,000 |  |  |  | (300,000 | ) |  |  | 619,000 |
Medical equipment |  |  | 2,403,000 |  |  |  | - |  |  |  | 2,403,000 |
Facilities |  |  | 4,697,000 |  |  |  | - |  |  |  | 4,697,000 |
ROU assets |  |  | 1,835,000 |  |  |  | - |  |  |  | 1,835,000 |
Unfavorable leasehold interests |  |  | (1,227,000 | ) |  |  | 451,000 |  |  |  | (776,000 | )
Total assets acquired |  |  | 12,015,000 |  |  |  | 151,000 |  |  |  | 12,166,000 |
Accounts payable |  |  | (150,000 | ) |  |  | - |  |  |  | (150,000 | )
Lease liabilities |  |  | (1,835,000 | ) |  |  | - |  |  |  | (1,835,000 | )
Deferred income taxes |  |  | (1,226,000 | ) |  |  | (88,000 | ) |  |  | (1,314,000 | )
Gain on bargain purchase |  |  | (3,679,000 | ) |  |  | (263,000 | ) |  |  | (3,942,000 | )
Base purchase consideration |  |  | 5,125,000 |  |  |  | (200,000 | ) |  |  | 4,925,000 |
Non-controlling interest |  |  | (2,100,000 | ) |  |  | 200,000 |  |  |  | (1,900,000 | )
CT Sim |  |  | (175,000 | ) |  |  | - |  |  |  | (175,000 | )
Cash paid by the Company |  | $ | 2,850,000 |  |  | $ | - |  |  | $ | 2,850,000 |

The Company recognized a bargain purchase, as defined by ASC 805, in connection with the RI Acquisition. The Company purchased the RI Companies as part of the sale of certain of GenesisCare’s assets in its bankruptcy proceedings, resulting in a bargain purchase. A bargain purchase gain of $263,000 and $3,942,000, net of deferred taxes of $88,000 and $1,314,000, respectively is reflected in other income in the condensed consolidated statements of operations for the three and nine-month periods ended September 30, 2024. None of the purchase price was allocated to intangible assets because none were acquired as part of the transaction. The Company recorded the unfavorable lease position received as part of the RI Acquisition as a reduction to ROU assets on the condensed consolidated balance sheet.

The preliminary value of the acquired tangible assets acquired were as follows:

|  | Fair Value |  |  | Average Useful Life (in Years) |
Facilities |  | $ | 4,697,000 |  |  |  | 15 |
Medical equipment |  |  | 2,403,000 |  |  |  | 4 |
Total medical equipment and facilities acquired |  | $ | 7,100,000 |  |  |  |  |

Costs related to legal, financial and due diligence services performed in connection with the RI Acquisition recorded in selling and administrative expense in the condensed consolidated statement of operations were $560,000 for the nine-month period ended September 30, 2024.

The net impact of the RI Acquisition on the consolidated results of operations, since the date of acquisition, are as follows:

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, 2024 |  |  | September 30, 2024 |
Revenue |  | $ | 2,635,000 |  |  | $ | 4,527,000 |
Operating income |  | $ | 188,000 |  |  | $ | 800,000 |

Per the guidance in ASC 805, the Company determined its consolidated financial results as if the RI Acquisition occurred on January 1, 2024. These pro forma results were based on estimates and assumptions, which the Company believes are reasonable. They are not the results that would have been realized had the Company and the RI Companies been combined during the periods presented and are not necessarily indicative of the Company’s consolidated results of operations in future periods. The pro forma results include adjustments related to purchase accounting. Acquisition costs and other nonrecurring charges are included in the earlier period presented. ASC 805 also requires presentation of proforma information for the comparable period, when the comparable period is presented. Due to the lack of reliable financial information for the RI Companies following the protracted bankruptcy proceedings, the Company was not able to obtain financial information sufficient to make these disclosures. Therefore, the Company has not made the comparable period proforma disclosure because it would be impracticable to do.

Following are the supplemental consolidated financial results of the Company on an unaudited, pro forma basis, as if the acquisition occurred on January 1, 2024. The supplemental proforma disclosure excludes the non-recurring impact from the bargain purchase gain generated from the RI Acquisition.

|  | Nine Months Ended |
|  | September 30, 2024 |
Revenue |  | $ | 22,701,000 |
Operating income |  | $ | 510,000 |
Diluted earnings per share |  | $ | 0.09 |

13

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report to the SEC may be deemed to contain certain forward-looking statements. The Private Securities Litigation Reform Act of 1995 has established that these statements qualify for safe harbors from liability. Forward-looking statements may include words like we “believe”, “anticipate”, “target”, “expect”, “pro forma”, “estimate”, “intend”, “will”, “is designed to”, “plan” and words of similar meaning. Forward-looking statements describe our future plans, objectives, expectations or goals. Such statements address future events and conditions and include, but are not limited to, such things as capital expenditures, earnings, liquidity and capital resources, financing of our business, government programs and regulations, legislation affecting the health care industry, the expansion of our proton beam radiation therapy business, accounting matters, compliance with debt covenants, completed and pending acquisitions, competition, customer concentration, contractual obligations, timing of payments, technology and interest rates. These forward-looking statements involve known and unknown risks that may cause our actual results in future periods to differ materially from those expressed in any forward-looking statement. Factors that could cause or contribute to such differences include, but are not limited to, such things as our level of debt, the limited market for our capital-intensive services, the impact of lowered federal reimbursement rates, the impact of U.S. health care reform legislation, competition and alternatives to our services, technological advances and the risk of equipment obsolescence, our significant investment in the proton beam radiation therapy business, restrictions in our debt agreements that limit our flexibility to operate our business, our ability to repay our indebtedness, our ability to integrate the RI Companies with our existing business, breaches in security of our information technology, the small and illiquid market for our stock. These lists are not all-inclusive because it is not possible to predict all factors. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the SEC, including the Annual Report on Form 10-K for the year ended December 31, 2023 and the definitive Proxy Statement for the Annual Meeting of Shareholders held on June 25, 2024. Any forward-looking statement speaks only as of the date such statement was made, and we are not obligated to update any forward-looking statement to reflect events or circumstances after the date on which such statement was made, except as required by applicable laws or regulations.

Overview

American Shared Hospital Services is a leading provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. The main drivers of the Company’s revenue are numbers of sites, procedure volume, and reimbursement. The Company delivers radiation therapy through medical equipment leasing and direct patient services, its two reportable segments. The medical equipment leasing segment, which we also refer to as the Company’s leasing segment, operates by fee-per-use contracts or revenue sharing contracts where the Company shares in the revenue and operating costs of the equipment. The Company leases ten Gamma Knife systems and one PBRT system as of September 30, 2024, where a contract exists between the hospital and the Company. On May 7, 2024, the Company acquired 60% of the equity interests of the RI Companies, which operate three single-unit radiation therapy facilities in Rhode Island. The Company, through GKF, owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. The Company also owns and operates a single-unit radiation therapy center in Puebla, Mexico, which began treating patients in July 2024. The Company’s facilities in Rhode Island, Peru, Ecuador, and Mexico are considered direct patient services, which we also refer to as the Company’s retail segment, where a contract exists between the Company’s facilities and the individual treated at the facility.

Based on the guidance provided in accordance with ASC 280, the Company determined it has two reportable segments, leasing and retail. See Note 1 - Basis of Presentation to the condensed consolidated financial statements for additional information. The Company’s Management’s Discussion and Analysis of Financial Condition and Results of Operations reflects activity for both segments and specifically addresses a segment when appropriate to the discussion.

Reimbursement

The Centers for Medicare and Medicaid (“CMS”) has established a 2024 delivery code reimbursement rate of approximately $7,420 ($7,691 in 2023) for a Medicare Gamma Knife treatment. The approximate CMS reimbursement rates for delivery of PBRT for a simple treatment without compensation for 2024 is $561 ($572 in 2023) and $1,362 ($1,323 in 2023) for simple with compensation, intermediate and complex treatments, respectively.

On September 29, 2020, CMS published a final rule that would have implemented a new mandatory payment model for radiation oncology services delivered to certain Medicare beneficiaries: the Radiation Oncology Alternative Payment Method (“RO APM”). On August 29, 2022, CMS published a final rule that delayed the start date of the RO APM to a date to be determined through future rulemaking and amended the definition of “model performance period” to provide that the start and end dates of the five-year model performance period will be established by CMS through future rulemaking. If the RO APM had not been delayed, it would have significantly altered CMS’ payment methodology from a fee for service paradigm to a set reimbursement by cancer type methodology for radiation services provided within a 90 day episode of care. Under the RO APM, hospital based and free-standing radiation therapy providers would have been required to participate in the model based on whether the radiation therapy provider is located within a randomly selected core-based statistical area. At this time, it is not clear if the RO APM will be implemented and, if it is implemented, the timing for implementation and in what form it will be implemented. If a start date for the RO APM is proposed, CMS will provide at least six months’ notice in advance of the proposed start date, and the proposed start date will be subject to public comment.

14

Application of Critical Accounting Policies and Estimates

The Company’s condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles and follow general practices within the industry in which it operates. Application of these principles requires management to make estimates, assumptions and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. These estimates, assumptions and judgments are based on information available as of the date of the condensed consolidated financial statements; accordingly, as this information changes, the condensed consolidated financial statements could reflect different estimates, assumptions and judgments. Certain policies inherently have a greater reliance on the use of estimates, assumptions and judgments and as such have a greater possibility of producing results that could be materially different than originally reported.

The most significant accounting policies followed by the Company are presented in Note 2 to the consolidated financial statements in the Company’s annual report on Form 10-K for the year ended December 31, 2023. These policies along with the disclosures presented in the other condensed consolidated financial statement notes and, in this discussion, and analysis, provide information on how significant assets and liabilities are valued in the condensed consolidated financial statements and how those values are determined. Based on the valuation techniques used and the sensitivity of financial statement amounts, and the methods, assumptions and estimates underlying those amounts, management has identified revenue recognition and costs of sales for turn-key and revenue sharing arrangements, accounting for business combinations, and the carrying value of property and equipment and useful lives, and as such the aforementioned could be most subject to revision as new information becomes available. The following are our critical accounting policies in which management’s estimates, assumptions and judgments most directly and materially affect the condensed consolidated financial statements:

Revenue Recognition

The Company recognizes revenues under ASC 842 and ASC 606. The Company had ten domestic Gamma Knife units, two international Gamma Knife units, three domestic LINAC units, and one PBRT system in operation in the United States as of September 30, 2024 and twelve domestic Gamma Knife units, two international Gamma Knife units, and one PBRT system in operation in the United States as of September 30, 2023. Five of the Company’s ten domestic Gamma Knife customers are under fee-per-use contracts, and five customers are under revenue sharing arrangements. The ten domestic Gamma Knife contracts operate under the Company’s leasing segment. The Company’s PBRT system at Orlando Health is considered a revenue share contract operating under the leasing segment. The Company’s three single-unit facilities, acquired in Rhode Island in May 2024, operate under the Company’s retail segment. The Company, through GKF, also owns and operates two single-unit, international Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. These two units economically operate under the Company’s retail segment.

Rental revenue from medical equipment leasing (“leasing”) – The Company recognizes revenues under ASC 842 when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s lease contracts typically have a ten-year term and are classified as either fee per use or revenue sharing. Fee per use revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company’s revenue sharing arrangements also have a cost sharing component and net profit share for the operating costs of the center. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs and profit. The operating costs and estimated net operating profit are recorded as other direct operating costs in the condensed consolidated statements of operations. For the three and nine-month periods ended September 30, 2024, the Company recognized leasing revenue of approximately $3,312,000 and $11,464,000 compared to $3,946,000 and $12,987,000 for the same periods in the prior year, respectively. Of the ASC 842 revenue, for the three and nine-month periods ended September 30, 2024, approximately $2,316,000 and $7,386,000 were for PBRT services compared to $2,219,000 and $7,078,000 for the same periods in the prior year, respectively.

Direct patient services income (“retail”) – The Company has stand-alone facilities in Lima, Peru, Guayaquil, Ecuador, and Puebla, Mexico where contracts exist between the Company’s facilities and the individual patients treated at the facility. Under ASC 606, the Company acts as the principal in these transactions and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife or radiation therapy treatment. Revenue related to these treatments is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru’s payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. GKCE’s patient population is primarily covered by a government payor and payments are paid between three and six months following issuance of an invoice. The facility in Puebla currently has a contract with one local hospital to cover its eligible patient base and is also treating self-pay patients. Puebla’s payment terms are typically prepaid for self-pay patients and net 30 days for the hospital patients. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts.

15

On May 7, 2024, the Company acquired 60% of the interests of the RI Companies. The RI Companies operate three, existing, stand-alone radiation therapy cancer centers in Woonsocket, Warwick and Providence, Rhode Island, where contracts exist between the Company’s facilities and the individual patients treated at the facility. Under ASC 606, the Company acts as the principal in these transactions and provides, at a point in time, a single performance obligation, in the form of radiation therapy treatment. Revenue related to radiation therapy is recognized at the expected amount to be received, based on insurance contracts and payor mix, when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. Payment terms at these facilities are typically prepaid for self-pay patients and insurance providers are paid net 30 to 60 days. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts. The Company also concluded the three radiation therapy facilities are part of its retail segment, see further discussion at Note 1 - Basis of Presentation to the condensed consolidated financial statements.

Accounts receivable balances under ASC 606 at September 30, 2024 and January 1, 2024 were $5,357,000 and $1,626,000, respectively. Accounts receivable balances under ASC 606 at September 30, 2023 and January 1, 2023 were $1,416,000 and $1,118,000, respectively. For the three and nine-month periods ended September 30, 2024, the Company recognized retail revenues of approximately $3,687,000 and $7,807,000 compared to $988,000 and $2,440,000 for the same periods in the prior year, respectively.

Salvage Value on Equipment

Salvage value is based on the estimated fair value of the equipment at the end of its useful life. The Company determines salvage value based on the estimated fair value of the equipment at the end of its useful life. There is no active resale market of Gamma Knife, LINAC or PBRT equipment, but the Company believes its salvage value estimates were a reasonable assessment of the economic value of the equipment when the contract ends. There is no salvage value assigned to the two international Gamma Knife units as of September 30, 2024. The Company also has not assigned salvage value to its PBRT or LINAC equipment as of September 30, 2024.

Business Combinations

Business combinations are accounted for under ASC 805 Business Combinations (“ASC 805”) using the acquisition method of accounting. Under the acquisition method of accounting, all assets acquired, identifiable intangible assets, liabilities assumed and applicable non-controlling interests are recognized at fair value as of the acquisition date. Costs incurred associated with the acquisition of a business are expensed as incurred. The allocation of purchase price requires management to make significant estimates and assumptions, especially with respect to tangible assets, any intangible assets identified and non-controlling interests. These estimates include, but are not limited to, a market participant’s expectation of future cash flows from acquired customers, acquired trade names, useful lives of acquired assets, and discount rates. See Note 11 - Rhode Island Acquisition to the condensed consolidated financial statements for further discussion on acquisitions.

Accounting Pronouncements Issued and Not Y et Adopted

In November 2023, the FASB issued ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) which enhances the disclosure requirements for segment reporting, primarily disclosures around significant segment expenses. The key provisions of the amendments require disclosure of significant segment expense reviewed by the CODM, require disclosure of an “other” segment category, require disclosure of segment profit or loss and assets for interim periods, clarify and require disclosure of other measurements used by the CODM in assessing segment performance and allocating resources, and require disclosure of the CODM's title and position and explanation of how the CODM assesses segment performance. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating ASU 2023-07 to determine the impact it may have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures (“ASU 2023-09”) which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company is currently evaluating ASU 2023-09 to determine the impact it may have on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (“ASU 2024-03”) which requires entities to 1. disclose amounts of (a) purchase of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and, (e) depreciation, depletion, and amortization recognized as part of oil-and gas-producing activities, 2. include certain amounts that are already required to be disclosed under current Generally Accepted Accounting Principles in the same disclosures as other disaggregation requirements, 3. disclose a qualitative description of the amounts remaining in relevant expense captions that are not necessarily disaggregated quantitatively, and 4. disclose the total amount of selling expenses, in annual reporting periods, an entity’s definition of selling expense. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating ASU 2024-03 to determine the impact it may have on its consolidated financial statements.

16

Third Quarter 2024 Results

Revenues increased by $1,865,000 and $3,644,000 to $6,999,000 and $19,271,000 for the three and nine-month periods ended September 30, 2024 compared to $5,134,000 and $15,627,000 for the same periods in the prior year, respectively. Revenues from the Company’s leasing segment decreased by $634,000 and $1,523,000 to $3,312,000 and $11,464,000 for the three and nine-month periods ended September 30, 2024 compared to $3,946,000 and $12,987,000 for the same periods in the prior year, respectively. The decrease in leasing revenue was driven by lower Gamma Knife volumes. Revenues from the Company’s retail segment increased by $2,699,000 and $5,367,000 to $3,687,000 and $7,807,000 for the three and nine-month periods ended September 30, 2024 compared to $988,000 and $2,440,000 for the same periods in the prior year, respectively. The increase in retail revenue was primarily due to revenue generated by the RI Companies following the closing of the RI Acquisition on May 7, 2024.

Revenues generated from the Company’s PBRT system increased by $97,000 and $308,000 to $2,316,000 and $7,386,000 for the three and nine-month periods ended September 30, 2024 compared to $2,219,000 and $7,078,000 for the same periods in the prior year, respectively. The increase for the three-month period ended September 30, 2024, was driven by higher volumes. The increase for the nine-month period ended September 30, 2024 was due to an increase in average reimbursement due to a shift in payor mix from Medicare to commercial or other payors, which are reimbursed at a higher rate.

The number of PBRT fractions increased by 64 and decreased by 330 to 1,252 and 3,764 for the three and nine-month periods ended September 30, 2024 compared to 1,188 and 4,094 for the same periods in the prior year, respectively. The decrease in PBRT volumes for the nine-month period ended September 30, 2024 was partially due to severe weather in Florida near the hospital where PBRT is provided, impacting patient scheduling.

Gamma Knife revenue decreased by $895,000 and $1,218,000 to $1,821,000 and $7,131,000 for the three and nine-month periods ended September 30, 2024 compared to $2,716,000 and $8,349,000 for the same periods in the prior year, respectively. The decrease in Gamma Knife revenue for the three and nine-month periods ended September 30, 2024 was due to a decrease in procedure volume from both the retail and leasing segments.

The number of Gamma Knife procedures decreased by 98 and 87 to 218 and 831 for the three and nine-month periods ended September 30, 2024 compared to 316 and 918 for the same periods in the prior year, respectively. The decrease in Gamma Knife procedures for the three-month period ended September 30, 2024 was driven by the leasing segment. The decrease in Gamma Knife procedures for the nine-month period was also due to the leasing segment and due to two customer contracts that expired during the second and third quarters of 2023. The decrease in Gamma Knife procedure volume for the nine-month period ended September 30, 2024 was offset by increases in procedure volume from the Company’s retail segment.

Gamma Knife procedures for the Company’s leasing segment decreased by 82 and 166 for the three and nine-month periods ended September 30, 2024, compared to the same periods in the prior year. The decrease in Gamma Knife procedures for the Company’s leasing segment for the three-month period ended September 30, 2024 was driven by downtime for an equipment upgrade at one customer location, one contract expiration that occurred in the third quarter of 2023 and staffing shortages at two of the customer locations. The decrease in Gamma Knife for the Company’s leasing segment procedures for the nine-month period ended September 30, 2024, was primarily due to two customer contracts that expired during the second and third quarters of 2023. The nine-month period ended September 30, 2024, was also impacted by downtime for equipment upgrades at two customer locations and staffing shortages at two of the customer locations. Gamma Knife procedures for the Company’s retail segment decreased by 16 and increased by 79 for the three and nine-month periods ended September 30, 2024, compared to the same periods in the prior year, due to improved marketing and physician outreach at the Company’s international locations. The Company also performed a Cobalt-60 reload and upgrade of the equipment at it s site in Ecuador in the fourth quarter of 2023. The replacement of the Cobalt-60 provides for faster treatment times.

The Company acquired the RI Companies on May 7, 2024 and included the financial results from their operations from May 7, 2024, the Closing Date of the transaction, through September 30, 2024. The Company’s stand-alone radiation therapy facility in Puebla, Mexico also began treating patients in July 2024. Radiation therapy revenues generated from the three stand-alone facilities acquired through the RI Acquisition and the radiation therapy facility in Puebla were $2,862,000 and $4,754,000 for the three and nine-month periods ended September 30, 2024, compared to $0 for the same periods in the prior year, respectively. Radiation therapy procedures for the three stand-alone facilities acquired through the RI Acquisition and the radiation therapy facility in Puebla were 5,186 and 7,785 for the three and nine-month periods ended September 30, 2024.

Total costs of revenue increased by $2,597,000 and $4,191,000 to $5,629,000 and $13,290,000 for the three and nine-month periods ended September 30, 2024 compared to $3,032,000 and $9,099,000 for the same periods in the prior year, respectively.

Maintenance and supplies and other direct operating costs, related party, increased by $74,000 and decreased by $109,000 to $783,000 and $2,181,000 for the three and nine-month periods ended September 30, 2024 compared to $709,000 and $2,290,000 for the same periods in the prior year, respectively. The increase in maintenance and supplies and other direct operating costs, related party, for the three-month period ended September 30, 2024, was driven by maintenance contracts for the equipment in Rhode Island. The decrease in maintenance and supplies and other direct operating costs, related party, for the nine-month period ended September 30, 2024 was due to the expiration of two service contracts that completed in the second and third quarters of 2023, with the related customer contracts. Since the fourth quarter of 2023, the Company has upgraded four of its existing Gamma Knife units to the Esprit. The new Esprit units are under warranty for the first year of service, also driving lower maintenance expense.

Depreciation and amortization increased by $438,000 and $606,000 to $1,666,000 and $4,418,000 for the three and nine-month periods ended September 30, 2024 compared to $1,228,000 and $3,812,000 for the same periods in the prior year, respectively. The increase in depreciation and amortization for the three and nine-month periods ended September 30, 2024 was due higher depreciation for upgraded equipment at four of the Company’s Gamma Knife locations, depreciation incurred for the equipment acquired in the RI Acquisition, and the Company’s new facility in Puebla, Mexico. These increases were offset by depreciation from the Company’s contract that expired in the third quarter of 2023. The equipment related to the second customer contract that expired, was fully depreciated prior to 2023.

Other direct operating costs increased by $2,085,000 and $3,694,000 to $3,180,000 and $6,691,000 for the three and nine-month periods ended September 30, 2024 compared to $1,095,000 and $2,997,000 for the same periods in the prior year, respectively. The increase in other direct operating costs for the three and nine-month periods ended September 30, 2024 was due to operating costs from the Company’s recently acquired facilities in Rhode Island and the Company’s new facility in Puebla, Mexico, which are part of the Company’s retail segment and have higher operating costs compared to facilities in the Company’s leasing segment.

Selling and administrative expense increased by $188,000 and $436,000 to $1,923,000 and $5,698,000 for the three and nine-month periods ended September 30, 2024 compared to $1,735,000 and $5,262,000 for the same periods in the prior year, respectively. The increase for the three-month period ended September 30, 2024 was due to higher personnel related costs and legal fees, partially attributable to the Company’s pursuit of new business opportunities, including the RI Acquisition. The increase in selling and administrative expense for the nine-month period ended September 30, 2024 was due to higher personnel related and other expense, partially attributable to the Company’s pursuit of new business opportunities, including the RI Acquisition, offset by lower rent expense.

17

Interest expense increased by $59,000 and $245,000 to $336,000 and $1,070,000 for the three and nine-month periods ended September 30, 2024 compared to $277,000 and $825,000 for the same periods in the prior year, respectively. The debt under the Credit Agreement carries a floating interest rate of SOFR plus 3%. The increase for the three and nine-month periods ended September 30, 2024 was due to an increase in SOFR and borrowings, including the Supplemental Term Loan received in January 2024, compared to the same periods of the prior year.

The Company recorded a $3,942,000 net bargain purchase gain related to the RI Acquisition that closed on May 7, 2024. The Company acquired 60% of the equity interests of the RI Companies, which operate three radiation therapy facilities, for $2,850,000. The assets acquired exceeded the total purchase price by the bargain purchase amount and the Company recorded this difference as a gain for the nine-month period ended September 30, 2024. During the three-month period ended September 30, 2024, the Company made adjustments to the initial provisional accounting for the RI Acquisition. The net impact of the adjustments resulted in an increase to the net bargain purchase gain of $263,000.

Interest and other income, net, decreased by $88,000 and $106,000 to $47,000 and $212,000 for the three and nine-month periods ended September 30, 2024 compared to $135,000 and $318,000 for the same periods in the prior year, respectively. The decrease for the three and nine-month periods ended September 30, 2024 was due to decreases in the interest received on the Company’s cash, due to lower average cash balances, compared to the same periods in the prior year, respectively.

Income tax expense decreased by $229,000 and $337,000 to an income tax benefit of $169,000 and $244,000 for the three and nine-month periods ended September 30, 2024 compared to income tax expense of $60,000 and $93,000 for the same periods in the prior year, respectively. The decrease in income tax expense for the three and nine-month periods ended September 30, 2024 was primarily due to losses incurred by the Company’s leasing segment, driven by lower Gamma Knife volume.

Net (income) loss attributable to non-controlling interests decreased by $250,000 and increased by $16,000 to a loss of $203,000 and $91,000 for the three and nine-month periods ended September 30, 2024 compared to income of $47,000 and a loss of $107,000 for the same periods in the prior year, respectively. Net income or loss attributable to non-controlling interests represents net income or loss earned by the 40% non-controlling interest in the Rhode Island facilities, the 19% non-controlling interest in GKF, and net income or loss of the non-controlling interests in various subsidiaries controlled by GKF. The decrease or increase in net income or loss attributable to non-controlling interests reflects the relative profitability of the three Rhode Island facilities and GKF.

Net (loss) income attributable to American Shared Hospital Services decreased by $325,000 and increased by $3,319,000 to a loss of $207,000, or $0.03 per diluted share and income of $3,514,000 or $0.54 per diluted share for the three and nine-month periods ended September 30, 2024 compared to net income of $118,000, or $0.02 per diluted share and net income of $195,000 or $0.03 per diluted share for the same periods in the prior year, respectively. The Company incurred a net loss for the three-month period ended September 30, 2024, primarily due to losses incurred by the leasing segment, driven by lower Gamma Knife volume, partially offset by net income from the retail segment. Net income increased for the nine-month period ended September 30, 2024 due to the bargain purchase gain generated from the RI Acquisition and net income earned from the Rhode Island facilities acquired, partially offset by increased total costs of revenue.

Liquidity and Capital Resources

The Company’s primary liquidity needs are to fund capital expenditures as well as support working capital requirements. In general, the Company’s principal sources of liquidity are cash and cash equivalents on hand and the $7,000,000 Revolving Line. As of September 30, 2024, the Company borrowed $4,500,000 on its Revolving Line. The Company had cash, cash equivalents and restricted cash of $14,077,000 at September 30, 2024 compared to $13,808,000 at December 31, 2023. The Company’s cash position increased by $269,000 during the first nine months of 2024 due to net advances on the Revolving Line of $2,000,000, net cash received from the RI Acquisition of $538,000, long-term debt financing of $2,700,000, and capital contributions of $38,000. These increases were offset by cash used by operating activities of $107,000, payment for the purchase of property and equipment of $3,278,000, payments on long-term debt of $1,430,000, debt issuance costs of $97,000 and distributions to non-controlling interests of $95,000. The Company’s expected primary cash needs on both a short and long-term basis are for capital expenditures, business expansion, working capital, and other general corporate purposes. The Company has scheduled interest and principal payments under its debt obligations of approximately $4,529,000 during the next 12 months.

Working Capital

The Company had working capital at September 30, 2024 of $8,159,000 compared to $9,677,000 at December 31, 2023. The $1,518,000 decrease in working capital was primarily due to increases in accounts payable, other and related party accrued liabilities, advances on the Revolving Line, and an increase in current portion of long-term debt offset by increases in accounts receivable. The Company believes that its cash on hand, cash flow from operations, and other cash resources are adequate to meet its scheduled debt obligations and working capital requirements during the next 12 months. See additional discussion in the “Commitments” section below. The Company, in the past, has secured financing for its Gamma Knife and radiation therapy units. The Company has secured financing for its projects from several lenders and anticipates that it will be able to secure financing on future projects from these or other lending sources, but there can be no assurance that financing will continue to be available on acceptable terms.

18

Long-Term Debt

On April 9, 2021, the Company and certain of its domestic subsidiaries entered into a five year $22,000,000 credit agreement with Fifth Third Bank, N.A., which refinanced its existing domestic Gamma Knife portfolio. The lease financing previously obtained by Orlando was also refinanced as long-term debt by the Credit Agreement. The Credit Agreement includes three loan facilities: (1) a $9,500,000 term loan (the “Term Loan”), which was used to refinance the domestic Gamma Knife debt and finance leases and the associated closing costs; (2) a $5,500,000 delayed draw term loan (the “DDTL”), which was used to refinance the Company’s PBRT finance leases and associated closing costs and to provide additional working capital for the Company; and (3) a $7,000,000 revolving line of credit (the “Revolving Line”), which is available for the Company’s future projects and general corporate purposes. The Company borrowed $4,500,000 under the Revolving Line as of September 30, 2024. The Credit Agreement is 48% amortized over a 58-month period with a balloon payment upon maturity and is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. The Revolving Loan, the Term Loan, and the DDTL will mature on April 9, 2026 unless accelerated due to the occurrence of certain events specified in the Credit Agreement. The Revolving Line is charged an unused line fee of 0.25% per annum. The Term Loan and DDTL have interest and principal payments due quarterly. Principal amortization on an annual basis for the Term Loan and DDTL equates to 48% of the original principal loan commitments in years one through five and an end of term payment of the remaining principal balance.

On January 25, 2024, the, the Company entered into a First Amendment to Credit Agreement with Fifth Third which amended the Credit Agreement to add the Supplemental Term Loan, a new term loan in the aggregate principal amount of $2,700,000. The proceeds of the Supplemental Term Loan were advanced in a single borrowing on January 25, 2024, and were used to finance capital expenditures that the Company paid cash for during 2023 for its operations in Puebla, Mexico and other related transaction costs. The Supplemental Term Loan will mature on January 25, 2030 (the “Maturity Date”), unless accelerated due to the occurrence of certain events specified in the Credit Agreement. Interest on the Supplemental Term Loan is payable monthly during the initial twelve month period following the First Amendment Effective Date. Following such twelve month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Supplemental Term Loan by the Maturity Date. The Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. The First Amendment also replaces the LIBOR-based rates in the Credit Agreement with SOFR-based rates. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%.

As of September 30, 2024, the Company was subject to customary covenants under the Credit Agreement which included, among other covenants and obligations, a minimum fixed charge coverage ratio of 1.25 to 1.0 and a total funded debt to EBITDA ratio of 3.0 to 1.0 (tested on a trailing twelve-month basis at the end of each fiscal quarter), along with an annual clean-up covenant that requires the Company to cause the outstanding principal balance under the Revolving Loan to be less than $3,500,000 for at least 30 consecutive days during each calendar year (the “Credit Agreement Covenants”). The Company was in compliance with the Credit Agreement Covenants as of September 30, 2024.

The Company’s acquisition of GKCE and the Gamma Knife Esprit in Ecuador is financed with DFC. The loan entered into with DFC in June 2020 was obtained through the Company's wholly-owned subsidiary, HoldCo, and is guaranteed by GKF. The DFC Loan is secured by a lien on GKCE’s assets. The first tranche of the DFC Loan was funded in June 2020. In October 2023, the second tranche of the DFC Loan was funded in the amount of $1,750,000 to finance its equipment upgrade in Ecuador. The amount outstanding under the first tranche of the DFC Loan is payable in 29 quarterly installments with a fixed interest rate of 3.67%. The amount outstanding under the second tranche of the DFC Loan is payable in 16 quarterly installments with a fixed interest rate of 7.49%.

The DFC Loan contains customary covenants including without limitation, requirements that HoldCo maintain certain financial ratios related to liquidity and cash flow as well as depository requirements. On March 28, 2024, HoldCo received a waiver and amendment from DFC for certain covenants as of December 31, 2023 and through December 31, 2024 and amended other covenants and definitions permanently. HoldCo was in compliance with all debt covenants pursuant to the DFC Loan as amended and waived at September 30, 2024.

The Company’s combined long-term debt, net of deferred issuance costs, totaled $14,375,000 as of September 30, 2024. See Note 3 - Long Term Debt to the condensed consolidated financial statements for additional information.

19

Commitments

As of September 30, 2024, the Company had commitments to purchase and install four Leksell Gamma Knife Esprit Systems (“Esprit”), one Gamma Plan workstation, and two Linear Accelerator (“LINAC”) systems. One LINAC and one Esprit will be placed at future customer sites. The remaining Esprit upgrades and LINACs are scheduled to occur during 2025 or later at existing customer sites. Total Gamma Knife and LINAC commitments as of September 30, 2024 were $13,383,000. There are no deposits on the condensed consolidated balance sheets related to these commitments as of September 30, 2024. It is the Company’s intent to finance substantially all of these commitments. There can be no assurance that financing will be available for the Company’s current or future projects, or at terms that are acceptable to the Company. However, the Company currently has cash on hand of $14,077,000 and its Revolving Line of $7,000,000 and is actively engaged with financing resources to fund these projects. The Company borrowed $4,500,000 on the Revolving Line as of September 30, 2024.

On September 4, 2022, the Company entered into a Maintenance and Support Agreement with Mevion, which provides for maintenance and support of the Company’s PBRT unit at Orlando Health from September 2022 through April 2026. The agreement requires the Company to make an annual prepayment of $1,939,000 for the current contractual period (one year). As of September 30, 2024, half of this prepayment was recorded as a prepaid contract and is being amortized over the one-year service period.

As of September 30, 2024, the Company had commitments to service and maintain its Gamma Knife, LINAC and PBRT equipment. The service commitments are carried out via contracts with Mevion, Elekta and Mobius Imaging, LLC. The Company’s commitment to purchase one LINAC system also includes a 5-year agreement to service the equipment, respectively. Total service commitments as of September 30, 2024 were $13,712,000. The Gamma Knife and certain other service contracts are paid monthly, as service is performed. The Company believes that cash flow from cash on hand and operations will be sufficient to cover these payments.

Related Party Transactions

The Company’s Gamma Knife business is operated through its 81% indirect interest in its GKF subsidiary. The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife. Since the Company purchases its Gamma Knife units from Elekta, there are significant related party transactions with Elekta, such as equipment purchases, commitments to purchase and service equipment, and costs to maintain the equipment.

The following table summarizes related party activity for the three and nine-month periods ended September 30, 2024 and 2023:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Equipment purchases and de-install costs |  | $ | 524,000 |  |  | $ | 2,147,000 |  |  | $ | 3,461,000 |  |  | $ | 3,565,000 |
Costs incurred to maintain equipment |  |  | 170,000 |  |  |  | 191,000 |  |  |  | 510,000 |  |  |  | 781,000 |
Total related party transactions |  | $ | 694,000 |  |  | $ | 2,338,000 |  |  | $ | 3,971,000 |  |  | $ | 4,346,000 |

The Company also had commitments to purchase and install four Esprit units, purchase two LINACs and service the related equipment of $19,068,000 as of September 30, 2024.

Related party liabilities on the condensed consolidated balance sheets consist of the following as of September 30, 2024 and December 31, 2023

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Accounts payable, asset retirement obligation and other accrued liabilities |  | $ | 4,138,000 |  |  | $ | 2,361,000 |

20

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The Company does not hold or issue derivative instruments for trading purposes and is not a party to any instruments with leverage or prepayment features. The Company does not have affiliation with partnerships, trusts or other entities whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements, and therefore has no exposure to the financing, liquidity, market or credit risks associated with such entities. At September 30, 2024, the Company had no significant long-term, market-sensitive investments.

21

Item 4. Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934. These controls and procedures are designed to ensure that material information relating to the Company and its subsidiaries is communicated to the principal executive officer and our principal financial officer. Based on that evaluation, our principal executive officer and our principal financial officer concluded that, as of September 30, 2024, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to the principal executive officer and our principal financial officer, and recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

The Company completed an acquisition on May 7, 2024. Many of the financial cycles are consistent with the Company’s current reporting cycles and, therefore, the related existing controls. The Company implemented new controls related to the revenue cycle for the RI Companies and will continue to assess the need for additional controls and resources through the year as it relates to the acquired operations. There were no other changes in our internal control over financial reporting during the three-month period ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

22

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors

There were no material changes during the period covered in this report to the risk factors previously disclosed in Part 1, Item 1A, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and Part II, Item 1A of the Company's Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information.

During the three-month period ended September 30, 2024, none of the Company’s directors or officers adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K

23

Item 6. Exhibit Index

|  |  |  | Incorporated by reference herein
Exhibit Number |  | Description |  | Form | Exhibit | Date
10.1 | • | Offer Letter between the Company to Mr. Gary Delanois dated October 4, 2024 |  | 8-K 001-08789 | 10.1 | 10/18/2024
31.1 | * | Certification of Principal Executive Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |
31.2 | * | Certification of Principal Financial Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |
32.1 | ǂ | Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |
101.INS | * | Inline XBRL Instance Document |  |  |  |
101.SCH | * | Inline XBRL Taxonomy Extension Schema Document |  |  |
101.CAL | * | Inline XBRL Taxonomy Calculation Linkbase Document |  |  |  |
101.DEF | * | Inline XBRL Taxonomy Definition Linkbase Document |  |  |
101.LAB | * | Inline XBRL Taxonomy Label Linkbase Document |  |  |  |
101.PRE | * | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |
104 | * | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline Instance XBRL contained in Exhibit 101 |  |  |  |
| * | Filed herewith. |  |  |  |
| ǂ | Furnished herewith. |  |  |  |
| # | Portions of this exhibit (indicated therein by asterisks) have been omitted for confidential treatment. |  |  |  |
| • | Indicates management compensatory plan, contract, or arrangement. |  |  |  |

24

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMERICAN SHARED HOSPITAL SERVICES

Registrant

Date: | November 14, 2024 | /s/ Raymond C. Stachowiak
|  | Raymond C. Stachowiak
|  | Executive Chairman of the Board and Chief Executive Officer (principal executive officer)
Date: | November 14, 2024 | /s/ Robert L. Hiatt
|  | Robert L. Hiatt
|  | Chief Financial Officer (principal financial and principal accounting officer)

25